Obstructive Sleep Apnea

Complex MONDO:0007147 Pathograph 8 Show in embeddings browser Respiratory Disease Sleep Disorder

Obstructive sleep apnea is a disorder of repetitive collapse of the upper airway during sleep, producing recurrent episodes of complete (apnea) or partial (hypopnea) airflow cessation despite continued respiratory effort. Reduced pharyngeal dilator muscle tone during sleep, often compounded by obesity, craniofacial anatomy, and increased airway collapsibility, leads to cycles of obstruction that terminate in arousals with intermittent hypoxemia and sleep fragmentation. The resulting sympathetic activation, oxidative stress, and systemic inflammation produce daytime sleepiness and contribute to hypertension, cardiovascular disease, and metabolic dysfunction.

Ask OpenScientist

Ask a research question about Obstructive Sleep Apnea. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

7
Pathophys.
8
Phenotypes
2
Gaps
8
Pathograph
2
Genes
7
Medical Actions
3
Datasets
5
References
2
Deep Research
🏷

Classifications

Harrison's Part
RESPIRATORY
?

Discussions and Knowledge Gaps

2
Does positive airway pressure (PAP) therapy mechanistically interrupt the OSA-driven cardiovascular pathways (intermittent hypoxia → oxidative stress → sympathetic activation → inflammation) to prevent cardiovascular events, or do improved intermediate parameters not reliably translate to hard cardiovascular endpoints?
KNOWLEDGE GAP OPEN kgap_osa_pap_cardiovascular_mechanism
Attached to
treatments#CPAP treatments#BiPAP
Obstructive sleep apnea has well-established pathophysiological mechanisms linking it to cardiovascular disease (intermittent hypoxia, sympathetic activation, oxidative stress, systemic inflammation). However, randomized controlled trials of PAP therapy show inconsistent results for reducing cardiovascular events and mortality, despite improvements in intermediate markers (apnea-hypopnea index, oxygen saturation, daytime sleepiness) and intermediate cardiometabolic parameters. This suggests that either (1) mechanistic pathways are disrupted by PAP in animal models but less effectively in humans, (2) intermediate-parameter improvement alone does not guarantee hard-endpoint benefit, or (3) treatment efficacy is dependent on phenotype-specific or adherence-dependent factors not yet characterized. The gap is not at the OSA pathophysiology level but at the PAP-therapy-response level: which OSA endotypes truly benefit from PAP, through which mechanism, and under which adherence/severity conditions.
Proposed experiments
Endotype-stratified PAP randomized cardiovascular outcome trial
endotype-stratified randomized controlled trial Relation: this experiment is of type this experiment type This experiment is of type endotype-stratified randomized controlled trial.
exp_osa_pap_endotype_stratified_rct
Enroll OSA patients prospectively phenotyped for physiological endotypes (loop gain, arousal threshold, upper-airway collapsibility, pharyngeal muscle responsiveness) and the hypoxic burden, then randomize to PAP versus control with hard cardiovascular endpoints (MACE, cardiovascular mortality). Test whether high-hypoxic-burden or sympathetically driven endotypes derive cardiovascular benefit that is diluted in unselected cohorts, clarifying which OSA endotypes truly benefit mechanistically.
Adherence-threshold dose-response analysis of PAP and cardiovascular events
adherence dose-response cohort analysis Relation: this experiment is of type this experiment type This experiment is of type adherence dose-response cohort analysis.
exp_osa_pap_adherence_doseresponse_mace
Using telemonitored objective PAP usage, model the dose-response relationship between nightly adherence hours and incident major adverse cardiovascular events, testing for an adherence threshold above which cardiovascular risk reduction emerges. This separates true biological inefficacy from undertreatment as the explanation for inconsistent RCT results, since prior trials averaged ~3-4 hours nightly use.
Show evidence (1 reference)
PMID:42276457 SUPPORT
"Although PAP therapy improves symptoms, apnea-hypopnea index, and intermediate cardiometabolic parameters-particularly among adherent patients-randomized controlled trials have yielded inconsistent results for reducing cardiovascular events and mortality."
The cited review documents the discrepancy between PAP's effects on intermediate markers and inconsistent RCT evidence for hard cardiovascular outcomes, highlighting the mechanistic uncertainty about whether PAP-induced improvement in intermediate parameters translates to cardiovascular event prevention.
What are the causal pathways by which intermittent hypoxia and sleep fragmentation in OSA drive fibrotic remodeling in the lungs, liver, kidneys, and heart, and which organ-specific TGF-beta, myofibroblast, and ECM-deposition mechanisms are cell-type specific versus shared across tissues?
KNOWLEDGE GAP OPEN kgap_osa_multiorgan_fibrosis
Attached to
pathophysiology#Intermittent Hypoxia pathophysiology#Sleep Fragmentation pathophysiology#Systemic Inflammation fibrotic_response:pathophysiology#Mesenchymal Cell Activation
Obstructive sleep apnea has established pathophysiological mechanisms linking intermittent hypoxia and sleep fragmentation to systemic inflammation and oxidative stress. However, the causal contribution of OSA to multi-organ fibrotic remodeling remains undercharacterized. Clinical and experimental evidence suggests OSA may promote fibrosis in the lungs, liver, kidneys, and heart, but the mechanistic details—how intermittent hypoxia-reoxygenation initiates TGF-beta signaling, myofibroblast activation, and ECM deposition in each organ—are incompletely defined. The degree to which fibrotic remodeling is reversible with therapy (e.g., CPAP) and the relative contributions of intermittent hypoxia versus sleep fragmentation to fibrotic progression remain understudied. Furthermore, organ-specific differences in fibrotic susceptibility and the role of tissue-resident macrophages, fibroblasts, and endothelial cells in OSA-driven remodeling require clarification. The TGF-beta → myofibroblast activation → ECM-deposition chain at issue is the conserved process modeled by the `fibrotic_response` module, so this gap is also anchored there as a candidate `conforms_to` target should the organ-specific evidence mature.
Proposed experiments
Prospective clinical study of OSA-related organ fibrosis progression by tissue type
prospective longitudinal imaging cohort study Relation: this experiment is of type this experiment type This experiment is of type prospective longitudinal imaging cohort study.
exp_osa_fibrosis_tissue_responders
Enroll OSA patients with serial imaging (high-resolution CT for lung, MRI for hepatic/renal fibrosis staging, echocardiography for cardiac fibrosis/stiffness) at baseline and 2-5 years, stratified by hypoxic burden and OSA severity, to quantify organ-specific fibrosis progression rates and identify which patients develop clinically significant remodeling.
Decision criterion
A hypoxic-burden-dependent increase in organ-specific fibrosis staging over 2-5 years (dose-response with OSA severity) supports intermittent hypoxia as a causal driver of remodeling; no progression above age-matched expectation argues against a causal OSA contribution at that organ.
Would support
pathophysiology#Intermittent Hypoxia
Would refute
fibrotic_response:pathophysiology#Mesenchymal Cell Activation
Mechanistic study of intermittent hypoxia-induced fibroblast activation in organ-specific contexts
organ-specific fibroblast hypoxia-reoxygenation model Relation: this experiment is of type this experiment type This experiment is of type organ-specific fibroblast hypoxia-reoxygenation model.
exp_osa_ih_fibroblast_activation
Expose primary fibroblasts isolated from lung, liver, kidney, and cardiac tissue to intermittent hypoxia-reoxygenation ex vivo, measuring TGF-beta autocrine signaling, α-smooth muscle actin (α-SMA) differentiation, pro-fibrotic gene expression (COL1A1, FN1, TIMP1/MMP2 ratio), and responses to anti-fibrotic therapies (pirfenidone, nintedanib). Test whether organ-specific fibroblast phenotypes show differential sensitivity to hypoxic cycles.
Decision criterion
Intermittent hypoxia-reoxygenation cycles inducing TGF-beta signaling and α-SMA+ myofibroblast conversion above normoxic controls establish that the hypoxia signal is sufficient to activate the conserved fibrotic program at the fibroblast level; absence of activation localizes the defect upstream (systemic/paracrine) rather than to a cell-autonomous fibroblast response.
Would support
fibrotic_response:pathophysiology#Mesenchymal Cell Activation pathophysiology#Intermittent Hypoxia
Randomized trial of OSA therapy efficacy on fibrotic progression
randomized controlled trial with biomarker endpoints Relation: this experiment is of type this experiment type This experiment is of type randomized controlled trial with biomarker endpoints.
exp_osa_fibrosis_therapy_reversibility
Enroll newly diagnosed moderate-to-severe OSA patients and randomize to PAP therapy versus control, with serial tissue biomarkers (circulating procollagen III, hyaluronic acid, tissue inhibitors of metalloproteinases) and imaging endpoints (fibrosis staging) at 6, 12, and 24 months. Determine whether therapy-induced reductions in intermittent hypoxia and sleep fragmentation arrest or reverse early fibrotic changes.
Decision criterion
Fibrosis-stage regression or biomarker decline in the PAP arm relative to control at 24 months supports OSA-driven remodeling being at least partly reversible and hypoxia/fragmentation being active causal drivers; no between-arm difference argues the remodeling is fixed or driven by OSA-independent comorbidity.
Would support
pathophysiology#Intermittent Hypoxia pathophysiology#Sleep Fragmentation
Would refute
fibrotic_response:pathophysiology#Mesenchymal Cell Activation
Show evidence (2 references)
PMID:42534659 SUPPORT Other
"Within this broader framework, fibrosis-linked structural remodeling emerges as an important yet under-supported dimension of OSA pathobiology"
The cited narrative review explicitly identifies fibrosis-linked remodeling as an emerging but under-supported dimension of OSA pathobiology.
PMID:42534659 SUPPORT Other
"Experimental and clinical evidence suggests that OSA may contribute to remodeling of the lungs, liver, kidneys, and heart, although the strength of the evidence and the degree of causal inference vary across organs."
Acknowledges that OSA may contribute to multi-organ fibrotic remodeling, but notes substantial variation in evidence strength and causal clarity across tissues.
⚙

Pathophysiology

7
Upper Airway Collapse
During sleep the wakefulness-dependent tonic drive to the pharyngeal dilator muscles is withdrawn, and where the underlying airway is anatomically narrow or collapsible the soft tissues occlude, obstructing airflow against continued respiratory effort. Anatomical factors (retrognathia, adenotonsillar hypertrophy, obesity and parapharyngeal fat) set the collapsibility, but they are not the whole mechanism: whether an individual obstruction becomes a self-limited event or the start of a cycling pattern depends on the non-anatomic endotypic traits curated in the node below.
Genioglossus pharyngeal dilator muscle cell CL:0002673 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Genioglossus pharyngeal dilator muscle cell, annotated with tongue muscle cell (CL:0002673). CL:0002673 is a cell type from the Cell Ontology.
Sleep-related loss of pharyngeal dilator muscle tone GO:0006937 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased Sleep-related loss of pharyngeal dilator muscle tone, annotated with regulation of muscle contraction (GO:0006937). GO:0006937 is a biological process from the Gene Ontology. ↓ DECREASED
pharynx UBERON:0001042 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in pharynx, annotated with chordate pharynx (UBERON:0001042). UBERON:0001042 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Sleep Fragmentation Each obstruction is terminated by a cortical arousal that restores airway patency, so the obstructive events and the arousals that end them are the same cycle.
Intermittent Hypoxia Cessation or reduction of airflow produces a fall in arterial oxygen saturation, restored rapidly when the arousal reopens the airway.
Show evidence (2 references)
PMID:38672697 SUPPORT
"BACKGROUND: Obstructive sleep apnea syndrome (OSAS), affecting approximately 1 billion adults globally, is characterized by recurrent airway obstruction during sleep, leading to oxygen desaturation, elevated carbon dioxide levels, and disrupted sleep architecture."
Defines the fundamental pathophysiological mechanism of OSA as recurrent airway obstruction during sleep.
PMID:36982552 SUPPORT
"Obstructive sleep apnea syndrome (OSAS) is characterized by intermittent hypoxia (IH) during sleep due to recurrent upper airway obstruction."
Confirms that intermittent hypoxia results from recurrent upper airway obstruction, the primary mechanical defect in OSA.
Intermittent Hypoxia
Repeated cycles of oxygen desaturation followed by rapid reoxygenation. The cyclical character is the mechanistically important part: it is the reoxygenation phase, ischaemia-reperfusion-like, that generates the burst of reactive oxygen species driving oxidative stress, sympathetic activation and systemic inflammation. An equivalent time-averaged desaturation delivered continuously does not reproduce the phenotype, which is why this node - and not the apnoea count - is the causal quantity for the systemic sequelae.
Response to Hypoxia GO:0001666 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased Response to Hypoxia (GO:0001666). GO:0001666 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Sympathetic Overactivation Cyclical hypoxia and reoxygenation sensitise the peripheral chemoreflex, carrying a nocturnal intermittent stimulus into a tonic daytime elevation of sympathetic vasoconstrictor outflow.
Systemic Inflammation Reoxygenation-driven reactive oxygen species activate NF-kB-dependent inflammatory signalling in the vascular wall.
Ocular Surface Inflammation and Dry Eye Disease Intermittent hypoxia and the associated oxidative stress drive ocular surface inflammation and lacrimal/meibomian gland dysfunction.
Show evidence (3 references)
PMID:38672697 SUPPORT
"The cyclic pattern of intermittent hypoxia in OSAS triggers oxidative stress, contributing to cellular damage."
Directly confirms that intermittent hypoxia in OSA triggers oxidative stress and cellular damage.
PMID:36982552 SUPPORT
"IH increases oxygen free radicals (ROS) and reduces antioxidant capacities."
Demonstrates the molecular mechanism by which intermittent hypoxia produces oxidative stress through increased ROS and decreased antioxidant defenses.
PMID:39694586 SUPPORT
"IH-induced oxidative stress (increased malondialdehyde (MDA) and NADPH oxidase (NOX) and decreased superoxide dismutase), increased inflammation (tumour necrosis factor-α, NF-κB and inducible nitric oxide synthase), HIF-1 and apoptosis evaluated by terminal deoxynucleotidyl transferase dUTP..."
Meta-analysis of rodent models confirming that intermittent hypoxia induces oxidative stress, inflammation, and apoptosis in the brain, establishing causal mechanisms.
Sleep Fragmentation
Frequent arousals to restore airway patency disrupt sleep architecture, reducing restorative sleep and causing daytime sleepiness. The arousal is simultaneously the corrective mechanism and a source of injury, which makes the arousal threshold genuinely double-edged rather than a severity marker: a low threshold is its own endotype, since patients who arouse too readily terminate events before dilator recruitment can stabilise the airway.
Sleep Regulation GO:0030431 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal Sleep Regulation, annotated with sleep (GO:0030431). GO:0030431 is a biological process from the Gene Ontology. ⚠ ABNORMAL
Downstream
Intermittent Hypoxia Arousal terminates each obstruction and restores airflow, producing the rapid reoxygenation that completes the hypoxia-reoxygenation cycle.
Show evidence (1 reference)
PMID:38672697 SUPPORT
"Obstructive sleep apnea syndrome (OSAS), affecting approximately 1 billion adults globally, is characterized by recurrent airway obstruction during sleep, leading to oxygen desaturation, elevated carbon dioxide levels, and disrupted sleep architecture."
Confirms that disrupted sleep architecture is a fundamental consequence of recurrent airway obstruction in OSA.
Non-Anatomic Endotypic Traits
Obstructive sleep apnoea is not one mechanism graded by severity. Careful physiological phenotyping identifies four largely independent contributing traits: pharyngeal collapsibility (the anatomic trait, measured as passive critical closing pressure), genioglossus muscle responsiveness during sleep, the arousal threshold, and respiratory control stability (loop gain). Around a third of patients each have minimal genioglossus responsiveness, a low arousal threshold, or high loop gain, and non-anatomic features contribute importantly in the majority. About one patient in five has a relatively non-collapsible airway similar to controls, and in those patients loop gain is roughly double - control instability substituting for anatomy. This node is curated because the apnoea-hypopnoea index by which the disease is graded is a count of events, not a measure of any of these traits, and because each trait implies a different therapeutic target.
nervous system control of respiratory gas exchange GO:0002087 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal nervous system control of respiratory gas exchange, annotated with regulation of respiratory gaseous exchange by nervous system process (GO:0002087). GO:0002087 is a biological process from the Gene Ontology. ⚠ ABNORMAL
Downstream
Sleep Fragmentation A low arousal threshold terminates respiratory events early, before dilator recruitment can stabilise the airway, increasing arousal frequency.
Upper Airway Collapse High loop gain and poor genioglossus responsiveness convert a marginal airway into a repeatedly collapsing one, so these traits act on the anatomic trigger rather than bypassing it.
Show evidence (3 references)
PMID:23721582 SUPPORT Human Clinical
"A total of 36% of patients with OSA had minimal genioglossus muscle responsiveness during sleep, 37% had a low arousal threshold, and 36% had high loop gain."
Quantifies the three non-anatomic traits in a phenotyped cohort, which is the evidence that this node is a real and common contributor rather than a theoretical refinement.
PMID:23721582 SUPPORT Human Clinical
"In these patients, loop gain was almost twice as high as patients with a Pcrit greater than -2 cm H2O"
Shows the trade-off between the anatomic and control arms directly: where the airway is comparatively non-collapsible, loop gain is roughly double.
PMID:23721582 SUPPORT Human Clinical
"This study confirms that OSA is a heterogeneous disorder. Although Pcrit-anatomy is an important determinant, abnormalities in nonanatomic traits are also present in most patients with OSA."
The study's own conclusion, and the reason this entry curates a non-anatomic node alongside the airway-collapse trigger rather than treating anatomy as the mechanism.
Sympathetic Overactivation
Chemoreceptor sensitisation converts a nocturnal, intermittent stimulus into a tonic daytime elevation of sympathetic vasoconstrictor outflow that persists long after waking - the step that turns a sleep disorder into a cardiovascular one - leading to hypertension, arrhythmias, and cardiovascular disease.
Sympathetic postganglionic neuron CL:0011103 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Sympathetic postganglionic neuron, annotated with sympathetic neuron (CL:0011103). CL:0011103 is a cell type from the Cell Ontology.
Show evidence (2 references)
PMID:38672697 SUPPORT
"The cyclic pattern of intermittent hypoxia in OSAS triggers oxidative stress, contributing to cellular damage."
Intermittent hypoxia triggers cellular stress that contributes to sympathetic activation and cardiovascular complications.
PMID:39595069 SUPPORT
"These agents, originally developed for T2D management, have demonstrated pleiotropic effects, including significant weight loss, blood pressure reduction, and amelioration of endothelial dysfunction and arterial stiffness, along with anti-inflammatory benefits, which may be particularly..."
Indicates that OSA is associated with blood pressure elevation, endothelial dysfunction, and arterial stiffness, consistent with sympathetic overactivation.
Systemic Inflammation
Intermittent hypoxia activates inflammatory pathways (NF-kB), elevating CRP, IL-6, and TNF-alpha. Contributes to metabolic dysfunction and atherosclerosis. Curated in parallel with sympathetic overactivation rather than downstream of it: the two limbs are additive contributors to the vascular consequences, and both are needed to account for the hypertension.
Vascular endothelial cell CL:0002139 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Vascular endothelial cell, annotated with endothelial cell of vascular tree (CL:0002139). CL:0002139 is a cell type from the Cell Ontology. Macrophage CL:0000235 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Macrophage (CL:0000235). CL:0000235 is a cell type from the Cell Ontology.
Inflammatory Response GO:0006954 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves Inflammatory Response (GO:0006954). GO:0006954 is a biological process from the Gene Ontology.
Show evidence (3 references)
PMID:38672697 SUPPORT
"The review delineates the imbalance between pro-inflammatory and anti-inflammatory factors in OSAS, leading to heightened oxidative stress."
Confirms that OSA is characterized by an imbalance favoring pro-inflammatory factors, resulting in heightened inflammation.
PMID:36982552 SUPPORT
"OS and metabolic alterations lead OSAS patients to undergo endothelial dysfunction, osteoporosis, systemic inflammation, increased cardiovascular risk, pulmonary remodeling, and neurological alterations."
Demonstrates that systemic inflammation is a key pathophysiological feature of OSA contributing to multiple complications.
PMID:39694586 SUPPORT
"IH-induced oxidative stress (increased malondialdehyde (MDA) and NADPH oxidase (NOX) and decreased superoxide dismutase), increased inflammation (tumour necrosis factor-α, NF-κB and inducible nitric oxide synthase), HIF-1 and apoptosis evaluated by terminal deoxynucleotidyl transferase dUTP..."
Meta-analysis evidence showing that intermittent hypoxia induces inflammation through TNF-α and NF-κB activation.
Ocular Surface Inflammation and Dry Eye Disease
Intermittent hypoxia and the associated oxidative stress in OSA drive ocular surface and systemic inflammation together with lacrimal gland dysfunction (reduced aqueous tear production) and meibomian gland dysfunction (dysregulated meibum lipid secretion). The resulting tear film instability produces both aqueous-deficient and evaporative dry eye disease. Mechanical factors such as face-down sleeping positions, habitual eye rubbing, and CPAP airflow leakage or retrograde air movement further aggravate meibomian gland dysfunction and ocular surface drying.
Meibomian (sebaceous) gland cell CL:2000021 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves abnormal Meibomian (sebaceous) gland cell, annotated with sebaceous gland cell (CL:2000021). CL:2000021 is a cell type from the Cell Ontology. ⚠ ABNORMAL
Ocular Surface Inflammation GO:0006954 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased Ocular Surface Inflammation, annotated with inflammatory response (GO:0006954). GO:0006954 is a biological process from the Gene Ontology. ↑ INCREASED Response to Oxidative Stress GO:0006979 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased Response to Oxidative Stress (GO:0006979). GO:0006979 is a biological process from the Gene Ontology. ↑ INCREASED Meibomian Lipid Metabolism GO:0006629 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves dysregulated Meibomian Lipid Metabolism, annotated with lipid metabolic process (GO:0006629). GO:0006629 is a biological process from the Gene Ontology. ↕ DYSREGULATED
Show evidence (3 references)
PMID:42412736 SUPPORT
"Tear film stability is disrupted by inflammation and lacrimal and meibomian glands dysfunction, which are caused by intermittent hypoxia and associated oxidative stress in OSA."
Establishes the mechanistic link: intermittent hypoxia and oxidative stress in OSA drive inflammation and lacrimal/meibomian gland dysfunction that destabilize the tear film.
PMID:42412736 SUPPORT
"These disruptions result in both aqueous-deficient and evaporative forms of DED."
Confirms that OSA-driven tear film disruption produces both aqueous-deficient and evaporative forms of dry eye disease.
PMID:42412736 SUPPORT
"This review highlights the multifactorial etiology of OSA-related DED, highlighting the roles of systemic and ocular inflammation, lipid metabolism dysfunction, and mechanical stress."
Supports the multifactorial mechanism, including ocular inflammation, meibomian lipid metabolism dysfunction, and mechanical stress.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Obstructive Sleep Apnea Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

8
Cardiovascular 2
Dry Eye Disease Keratoconjunctivitis sicca HP:0001097 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Dry eye disease, annotated with Keratoconjunctivitis sicca (HP:0001097). HP:0001097 is a phenotype from the Human Phenotype Ontology.
Aqueous-deficient and evaporative dry eye from OSA-related tear film instability
Show evidence (1 reference)
PMID:42412736 SUPPORT
"Obstructive Sleep Apnea (OSA) and Dry Eye Disease (DED) are increasingly recognized as interrelated conditions with significant clinical implications."
Confirms dry eye disease as a recognized ocular comorbidity of obstructive sleep apnea.
Hypertension FREQUENT HP:0000822 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hypertension (HP:0000822). HP:0000822 is a phenotype from the Human Phenotype Ontology.
Often resistant to treatment
Show evidence (2 references)
PMID:39595069 SUPPORT
"These agents, originally developed for T2D management, have demonstrated pleiotropic effects, including significant weight loss, blood pressure reduction, and amelioration of endothelial dysfunction and arterial stiffness, along with anti-inflammatory benefits, which may be particularly..."
Indicates that blood pressure elevation is a characteristic feature of OSA requiring therapeutic intervention.
PMID:38672697 SUPPORT
"OSAS-related complications include cardiovascular disorders, neurological impairments, metabolic dysfunction, and a potential link to cancer."
Confirms that cardiovascular disorders, including hypertension, are a major complication of OSA.
Genitourinary 1
Nocturia FREQUENT HP:0000017 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Nocturia (HP:0000017). HP:0000017 is a phenotype from the Human Phenotype Ontology.
Nervous System 5
Snoring VERY_FREQUENT HP:0025267 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Snoring (HP:0025267). HP:0025267 is a phenotype from the Human Phenotype Ontology.
Witnessed Apneas VERY_FREQUENT Sleep apnea HP:0010535 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Sleep Apnea (HP:0010535). HP:0010535 is a phenotype from the Human Phenotype Ontology.
Excessive Daytime Sleepiness VERY_FREQUENT Excessive daytime somnolence HP:0001262 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Excessive Daytime Somnolence (HP:0001262). HP:0001262 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:39595069 SUPPORT
"Emerging clinical evidence suggests that GLP-1RAs and SGLT2 inhibitors can reduce OSA severity and improve daytime sleepiness, potentially reversing the adverse cardiovascular effects observed in OSA."
Confirms that daytime sleepiness is a characteristic symptom of OSA that can be ameliorated with treatment.
Morning Headaches FREQUENT HP:0002315 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Headache (HP:0002315). HP:0002315 is a phenotype from the Human Phenotype Ontology.
Cognitive Impairment FREQUENT HP:0100543 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Cognitive Impairment (HP:0100543). HP:0100543 is a phenotype from the Human Phenotype Ontology.
Memory, attention deficits
Show evidence (2 references)
PMID:38672697 SUPPORT
"OSAS significantly impacts quality of life and is associated with increased morbidity and mortality, particularly in the cardiovascular and cognitive domains."
Confirms that cognitive impairment is a major domain of morbidity in OSA.
PMID:39694586 SUPPORT
"Obstructive sleep apnoea (OSA) contributes to cerebrovascular diseases and cognitive decline."
Establishes the link between OSA and cognitive decline, supported by rodent model evidence of brain injury from intermittent hypoxia.
🧬

Genetic Associations

2
PHOX2B (Risk Factor)
Gene: PHOX2B hgnc:9143 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is PHOX2B (hgnc:9143). hgnc:9143 is a gene from the HUGO Gene Nomenclature Committee.
Craniofacial genes (Risk Factor)
💊

Medical Actions

7
CPAP
Action: continuous positive airway pressure ventilationNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is continuous positive airway pressure ventilation, annotated with Continuous Positive Airway Pressure (NCIT:C124040). NCIT:C124040 is a clinical intervention from the NCI Thesaurus. Ontology label: Continuous Positive Airway Pressure NCIT:C124040
Continuous positive airway pressure, gold standard treatment.
Mechanism Target:
INHIBITS Sleep Fragmentation — Positive pressure splints the pharynx open across the respiratory cycle, abolishing the obstruction-arousal cycle and, with it, the intermittent hypoxia downstream. Because it removes the events without altering obesity or craniofacial anatomy, reversal of the downstream chain under CPAP is the causal test that the events themselves drive it.
INHIBITS Upper Airway Collapse — Pneumatic splinting acts directly on the anatomic trigger; it does not correct the non-anatomic endotypic traits, which is one reason residual symptoms persist in some adherent patients.
Show evidence (2 references)
PMID:42276457 SUPPORT Human Clinical
"Although PAP therapy improves symptoms, apnea-hypopnea index, and intermediate cardiometabolic parameters-particularly among adherent patients-randomized controlled trials have yielded inconsistent results for reducing cardiovascular events and mortality."
CPAP (positive airway pressure) improves symptoms and the apnea-hypopnea index, establishing it as the primary therapy for OSA, though cardiovascular endpoint benefit is adherence-dependent.
PMID:41820035 SUPPORT Other
"CPAP is recommended as the default modality due to lower cost (1, A)."
The 2025 Chinese Thoracic Society guideline recommends CPAP as the default positive airway pressure modality for obstructive sleep apnea.
BiPAP
Action: bi-level positive airway pressure ventilationNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is bi-level positive airway pressure ventilation, annotated with Biphasic Positive Airway Pressure (NCIT:C124039). NCIT:C124039 is a clinical intervention from the NCI Thesaurus. Ontology label: Biphasic Positive Airway Pressure NCIT:C124039
Bilevel positive airway pressure for some patients.
Show evidence (1 reference)
PMID:42276457 SUPPORT Human Clinical
"This review examines the pathophysiological mechanisms linking OSA to cardiovascular disease, and evaluates current evidence regarding the impact of positive airway pressure (PAP) therapy on cardiovascular outcomes and mortality."
Bilevel PAP is a positive airway pressure modality; the review evaluates PAP therapy as the mainstay intervention for OSA and its cardiovascular impact.
Oral Appliances
Action: oral appliance therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is oral appliance therapy (NCIT:C157943). NCIT:C157943 is a clinical intervention from the NCI Thesaurus. Ontology label: Oral Appliance Therapy NCIT:C157943
Mandibular advancement devices for mild-moderate OSA.
Show evidence (1 reference)
PMID:26094920 SUPPORT Human Clinical
"We recommend that sleep physicians consider prescription of oral appliances, rather than no treatment, for adult patients with obstructive sleep apnea who are intolerant of CPAP therapy or prefer alternate therapy."
The AASM/AADSM clinical practice guideline recommends oral appliance therapy for adults with OSA who are CPAP-intolerant or prefer an alternative.
Weight Loss
Action: dietary interventionNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is dietary intervention (NCIT:C15447). NCIT:C15447 is a clinical intervention from the NCI Thesaurus. Ontology label: Dietary Intervention NCIT:C15447
Can significantly reduce or resolve OSA.
Show evidence (1 reference)
PMID:39595069 SUPPORT Human Clinical
"Emerging clinical evidence suggests that GLP-1RAs and SGLT2 inhibitors can reduce OSA severity and improve daytime sleepiness, potentially reversing the adverse cardiovascular effects observed in OSA."
Weight loss (here achieved pharmacologically with GLP-1RAs) reduces OSA severity and improves daytime sleepiness, supporting weight reduction as an OSA-modifying intervention.
Positional Therapy
Avoiding supine sleep position.
Surgery
Action: surgical procedureNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is surgical procedure (NCIT:C15329). NCIT:C15329 is a clinical intervention from the NCI Thesaurus. Ontology label: Surgical Procedure NCIT:C15329
UPPP, maxillomandibular advancement for selected patients.
Hypoglossal Nerve Stimulation
Action: hypoglossal nerve stimulationNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is hypoglossal nerve stimulation, annotated with Peripheral Nerve Stimulation (NCIT:C21025). NCIT:C21025 is a clinical intervention from the NCI Thesaurus. Ontology label: Peripheral Nerve Stimulation NCIT:C21025
Implantable device for CPAP-intolerant patients.
Show evidence (2 references)
PMID:24401051 SUPPORT Human Clinical
"We evaluated the clinical safety and effectiveness of upper-airway stimulation at 12 months for the treatment of moderate-to-severe obstructive sleep apnea."
The STAR trial evaluated upper-airway (hypoglossal nerve) stimulation as an implantable therapy for moderate-to-severe OSA in patients unable to adhere to CPAP.
PMID:24401051 SUPPORT Human Clinical
"The median AHI score at 12 months decreased 68%, from 29.3 events per hour to 9.0 events per hour (P<0.001)"
Hypoglossal nerve stimulation produced a significant 68% reduction in the apnea-hypopnea index at 12 months, demonstrating objective efficacy.
🌍

Environmental Factors

5
Obesity
Major modifiable risk factor
Show evidence (1 reference)
PMID:11122588 SUPPORT Human Clinical
"A 10% increase in weight predicted a 6-fold (95% CI, 2.2-17.0) increase in the odds of developing moderate-to-severe SDB"
Wisconsin Sleep Cohort, measured prospectively at 4-year intervals. The reciprocal finding -- 10% weight loss predicting a 26% AHI reduction -- is what makes this exposure modifiable rather than merely associated.
Alcohol Consumption
exposure to alcohol consumption ECTO:0001082 Environmental Conditions, Treatments and Exposures Ontology (ECTO) Relation: this environmental factor is this exposure This environmental factor is exposure to alcohol consumption (ECTO:0001082). ECTO:0001082 is an exposure from the Environmental Conditions, Treatments and Exposures Ontology.
Alcohol use is associated with OSA (OR 1.33); upper airway muscle relaxation is the proposed mechanism
Show evidence (1 reference)
PMID:29971810 SUPPORT Human Clinical
"The odds ratio for OSA increased almost 1.33 times"
Meta-analysis of 14 observational studies; 95% CI 1.10-1.62 (omitted from the snippet because the validator strips bracketed text). PARTIAL, and the note was rewritten: this measures the association, not the airway-relaxation mechanism the note previously asserted, and the authors grade the overall evidence low to very low.
Sedatives
Worsen airway collapse
Show evidence (1 reference)
PMID:16424433 SUPPORT Other
"sedative, analgesic, and anesthetic agents, which can worsen OSAS by decreasing pharyngeal tone"
States the mechanism this annotation records -- loss of pharyngeal tone, plus blunted arousal responses to hypoxia and hypercarbia. OTHER because the quoted sentence is a review's mechanistic synthesis.
Supine Sleep Position
supine sleep position XCO:0000084 Experimental Conditions Ontology (XCO) Relation: this environmental factor is this exposure This environmental factor is supine sleep position, annotated with supine position (XCO:0000084). XCO:0000084 is an exposure from the Experimental Conditions Ontology.
Increases apnea events
Show evidence (1 reference)
PMID:28012784 SUPPORT Human Clinical
"found benefit for positional modification techniques in those with supine OSA in terms of reduction in apnea-hypopnea index (AHI) and time spent supine"
Meta-analysis of randomized trials. Interventional rather than observational evidence: preventing supine sleep lowers the AHI, so the position is acting on apnea events rather than merely co-occurring with them. CPAP remained more effective.
Nasal Congestion
Increases upper airway resistance
Show evidence (1 reference)
PMID:11427099 SUPPORT Human Clinical
"for habitual snoring with severe (always or almost always) nasal congestion vs none was 3.0"
Wisconsin Sleep Cohort, 4,916 participants, adjusted for sex, age, body habitus and smoking. PARTIAL and worth reading carefully: the outcome is habitual snoring, and the authors state the association was NOT explained by snorers with frank sleep apnea -- so this supports raised upper airway resistance, not an apnea-event increase.
🔬

Biochemical Markers

3
Oxygen Saturation (Decreased)
Context: Nocturnal desaturations
CRP (Elevated)
Context: Systemic inflammation
Catecholamines (Elevated)
Context: Sympathetic activation
🔬

Diagnosis

1
Polysomnography
Attended in-laboratory polysomnography is the reference standard for diagnosing obstructive sleep apnea, quantifying the apnea-hypopnea index, and is also preferred for precise assessment of treatment efficacy and follow-up.
polysomnography NCIT:C114185 NCI Thesaurus (NCIT)
Results: Apnea-hypopnea index establishing the presence and severity of obstructive sleep apnea.
Show evidence (2 references)
PMID:41820035 SUPPORT Other
"PSG is the gold standard for diagnosing OSA in adults (1, A)."
The 2025 Chinese Thoracic Society guideline designates polysomnography the gold standard diagnostic test for obstructive sleep apnea in adults.
PMID:41820035 SUPPORT Other
"Screening is recommended for individuals at high risk for OSA who exhibit typical symptoms or physical signs, or who have relevant comorbidities."
The guideline recommends screening high-risk individuals with typical symptoms, physical signs, or relevant comorbidities, which precedes diagnostic polysomnography.
📊

Related Datasets

3
Differential expression profiles of plasma exosomal microRNAs in obstructive sleep apnea patients geo:GSE282864
Obstructive sleep apnea (OSA) is a prevalent respiratory disorder, with an estimated global prevalence of over one billion individuals, exhibiting a wide spectrum of severity. In this study, clinical data and whole blood samples were obtained from non-OSA individuals and OSA patients.we performed high-throughput sequencing to analyze differential expression of miRNAs between non-OSA exosomes (n=4) and OSA-Exos (n=6). This analysis identified 15 miRNAs exhibited significantly different expression levels between the two groups, with 7 upregulated and 8 downregulated in OSA-Exos compared to CON-Exos.
human BULK RNA SEQ n=10
PMID:40505833
Identified by GEO DataSets index search for Obstructive Sleep Apnea (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-07-31. Title, sample count, and organism are GEO's own values.
Differential Expression and Correlation Analysis of Global Transcriptome for Obstructive Sleep Apnea Hypopnea Syndrome geo:GSE293433
In order to investigate the gene expression patterns and molecular regulatory mechanisms of obstructive sleep apnea hypopnea syndrome (OSAHS), the global transcriptome expression profiles of OSAHS patients and healthy people were analyzed using transcriptome sequencing technology. Differential expression of circular RNA, microRNA, long noncoding RNA, and messenger RNA was investigated between the two groups.
human BULK RNA SEQ n=10
PMID:40264951
Identified by GEO DataSets index search for Obstructive Sleep Apnea (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-07-31. Title, sample count, and organism are GEO's own values.
Integrative Analysis of Genome-Wide Epigenetic and Transcriptomic Alterations Reveals Molecular Markers for Diagnosing Pediatric Obstructive Sleep Apnea in Black Females [RNA-Seq] geo:GSE237281
This study explores the epigentic and transcriptomic changes associated with pediatric obstructive sleep apnea in Black female patients. By analyzing saliva samples, the study identifies dysregulated pathways and specific molecular markers, emphasizing the need for accessible diagnostic tools and addressing healthcare disparities in underrepresented population. The non-invasive approach using saliva samples offers potential for future research and improved diagnostics for pediatric OSA.
human BULK RNA SEQ n=19
PMID:39717585
Identified by GEO DataSets index search for Obstructive Sleep Apnea (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-07-31. Title, sample count, and organism are GEO's own values.
{ }

Source YAML

click to show 
name: Obstructive Sleep Apnea
creation_date: '2025-12-18T17:01:35Z'
description: >-
  Obstructive sleep apnea is a disorder of repetitive collapse of the upper
  airway during sleep, producing recurrent episodes of complete (apnea) or
  partial (hypopnea) airflow cessation despite continued respiratory effort.
  Reduced pharyngeal dilator muscle tone during sleep, often compounded by
  obesity, craniofacial anatomy, and increased airway collapsibility, leads to
  cycles of obstruction that terminate in arousals with intermittent hypoxemia
  and sleep fragmentation. The resulting sympathetic activation, oxidative
  stress, and systemic inflammation produce daytime sleepiness and contribute to
  hypertension, cardiovascular disease, and metabolic dysfunction.
category: Complex
parents:
- Respiratory Disease
- Sleep Disorder
disease_term:
  preferred_term: obstructive sleep apnea syndrome
  term:
    id: MONDO:0007147
    label: obstructive sleep apnea syndrome
pathophysiology:
- name: Upper Airway Collapse
  description: >
    During sleep the wakefulness-dependent tonic drive to the pharyngeal
    dilator muscles is withdrawn, and where the underlying airway is
    anatomically narrow or collapsible the soft tissues occlude, obstructing
    airflow against continued respiratory effort. Anatomical factors
    (retrognathia, adenotonsillar hypertrophy, obesity and parapharyngeal fat)
    set the collapsibility, but they are not the whole mechanism: whether an
    individual obstruction becomes a self-limited event or the start of a
    cycling pattern depends on the non-anatomic endotypic traits curated in the
    node below.
  role: trigger
  biological_scale: TISSUE
  conforms_to: "sleep_disordered_breathing_intermittent_hypoxia#Sleep-Related Loss of Upper Airway Dilator Compensation in a Collapsible Pharynx"
  cell_types:
  - preferred_term: Genioglossus pharyngeal dilator muscle cell
    term:
      id: CL:0002673
      label: tongue muscle cell
  biological_processes:
  - preferred_term: Sleep-related loss of pharyngeal dilator muscle tone
    term:
      id: GO:0006937
      label: regulation of muscle contraction
    modifier: DECREASED
  locations:
  - preferred_term: pharynx
    term:
      id: UBERON:0001042
      label: chordate pharynx
  downstream:
  - target: Sleep Fragmentation
    description: >-
      Each obstruction is terminated by a cortical arousal that restores airway
      patency, so the obstructive events and the arousals that end them are the
      same cycle.
    causal_link_type: DIRECT
  - target: Intermittent Hypoxia
    description: >-
      Cessation or reduction of airflow produces a fall in arterial oxygen
      saturation, restored rapidly when the arousal reopens the airway.
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:38672697
    reference_title: "Unraveling the Complexities of Oxidative Stress and Inflammation Biomarkers in Obstructive Sleep Apnea Syndrome: A Comprehensive Review."
    supports: SUPPORT
    snippet: "BACKGROUND: Obstructive sleep apnea syndrome (OSAS), affecting approximately
      1 billion adults globally, is characterized by recurrent airway obstruction
      during sleep, leading to oxygen desaturation, elevated carbon dioxide levels,
      and disrupted sleep architecture."
    explanation: "Defines the fundamental pathophysiological mechanism of OSA as recurrent
      airway obstruction during sleep."
  - reference: PMID:36982552
    reference_title: "Molecular Pathology, Oxidative Stress, and Biomarkers in Obstructive Sleep Apnea."
    supports: SUPPORT
    snippet: "Obstructive sleep apnea syndrome (OSAS) is characterized by intermittent
      hypoxia (IH) during sleep due to recurrent upper airway obstruction."
    explanation: "Confirms that intermittent hypoxia results from recurrent upper
      airway obstruction, the primary mechanical defect in OSA."
- name: Intermittent Hypoxia
  description: >
    Repeated cycles of oxygen desaturation followed by rapid reoxygenation.
    The cyclical character is the mechanistically important part: it is the
    reoxygenation phase, ischaemia-reperfusion-like, that generates the burst of
    reactive oxygen species driving oxidative stress, sympathetic activation and
    systemic inflammation. An equivalent time-averaged desaturation delivered
    continuously does not reproduce the phenotype, which is why this node - and
    not the apnoea count - is the causal quantity for the systemic sequelae.
  role: central_effector
  biological_scale: ORGANISM
  conforms_to: "sleep_disordered_breathing_intermittent_hypoxia#Chronic Intermittent Hypoxia and Reoxygenation"
  biological_processes:
  - preferred_term: Response to Hypoxia
    term:
      id: GO:0001666
      label: response to hypoxia
    modifier: INCREASED
  downstream:
  - target: Sympathetic Overactivation
    description: >-
      Cyclical hypoxia and reoxygenation sensitise the peripheral chemoreflex,
      carrying a nocturnal intermittent stimulus into a tonic daytime elevation
      of sympathetic vasoconstrictor outflow.
    causal_link_type: DIRECT
  - target: Systemic Inflammation
    description: >-
      Reoxygenation-driven reactive oxygen species activate NF-kB-dependent
      inflammatory signalling in the vascular wall.
    causal_link_type: DIRECT
  - target: Ocular Surface Inflammation and Dry Eye Disease
    description: >-
      Intermittent hypoxia and the associated oxidative stress drive ocular
      surface inflammation and lacrimal/meibomian gland dysfunction.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  evidence:
  - reference: PMID:38672697
    reference_title: "Unraveling the Complexities of Oxidative Stress and Inflammation Biomarkers in Obstructive Sleep Apnea Syndrome: A Comprehensive Review."
    supports: SUPPORT
    snippet: "The cyclic pattern of intermittent hypoxia in OSAS triggers oxidative
      stress, contributing to cellular damage."
    explanation: "Directly confirms that intermittent hypoxia in OSA triggers oxidative
      stress and cellular damage."
  - reference: PMID:36982552
    reference_title: "Molecular Pathology, Oxidative Stress, and Biomarkers in Obstructive Sleep Apnea."
    supports: SUPPORT
    snippet: "IH increases oxygen free radicals (ROS) and reduces antioxidant capacities."
    explanation: "Demonstrates the molecular mechanism by which intermittent hypoxia
      produces oxidative stress through increased ROS and decreased antioxidant defenses."
  - reference: PMID:39694586
    reference_title: "Cerebral oxidative stress, inflammation and apoptosis induced by intermittent hypoxia: a systematic review and meta-analysis of rodent data."
    supports: SUPPORT
    snippet: "IH-induced oxidative stress (increased malondialdehyde (MDA) and NADPH
      oxidase (NOX) and decreased superoxide dismutase), increased inflammation (tumour
      necrosis factor-α, NF-κB and inducible nitric oxide synthase), HIF-1 and apoptosis
      evaluated by terminal deoxynucleotidyl transferase dUTP nick-end labelling and
      cleaved caspase-3."
    explanation: "Meta-analysis of rodent models confirming that intermittent hypoxia
      induces oxidative stress, inflammation, and apoptosis in the brain, establishing
      causal mechanisms."
- name: Sleep Fragmentation
  description: >
    Frequent arousals to restore airway patency disrupt sleep architecture,
    reducing restorative sleep and causing daytime sleepiness. The arousal is
    simultaneously the corrective mechanism and a source of injury, which makes
    the arousal threshold genuinely double-edged rather than a severity marker: a
    low threshold is its own endotype, since patients who arouse too readily
    terminate events before dilator recruitment can stabilise the airway.
  role: amplifier
  biological_scale: ORGANISM
  conforms_to: "sleep_disordered_breathing_intermittent_hypoxia#Recurrent Apnoea-Hypopnoea with Arousal from Sleep"
  biological_processes:
  - preferred_term: Sleep Regulation
    term:
      id: GO:0030431
      label: sleep
    modifier: ABNORMAL
  downstream:
  - target: Intermittent Hypoxia
    description: >-
      Arousal terminates each obstruction and restores airflow, producing the
      rapid reoxygenation that completes the hypoxia-reoxygenation cycle.
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:38672697
    reference_title: "Unraveling the Complexities of Oxidative Stress and Inflammation Biomarkers in Obstructive Sleep Apnea Syndrome: A Comprehensive Review."
    supports: SUPPORT
    snippet: "Obstructive sleep apnea syndrome (OSAS), affecting approximately 1 billion
      adults globally, is characterized by recurrent airway obstruction during sleep,
      leading to oxygen desaturation, elevated carbon dioxide levels, and disrupted
      sleep architecture."
    explanation: "Confirms that disrupted sleep architecture is a fundamental consequence
      of recurrent airway obstruction in OSA."
- name: Non-Anatomic Endotypic Traits
  description: >-
    Obstructive sleep apnoea is not one mechanism graded by severity. Careful
    physiological phenotyping identifies four largely independent contributing
    traits: pharyngeal collapsibility (the anatomic trait, measured as passive
    critical closing pressure), genioglossus muscle responsiveness during sleep,
    the arousal threshold, and respiratory control stability (loop gain). Around
    a third of patients each have minimal genioglossus responsiveness, a low
    arousal threshold, or high loop gain, and non-anatomic features contribute
    importantly in the majority. About one patient in five has a relatively
    non-collapsible airway similar to controls, and in those patients loop gain
    is roughly double - control instability substituting for anatomy. This node
    is curated because the apnoea-hypopnoea index by which the disease is graded
    is a count of events, not a measure of any of these traits, and because each
    trait implies a different therapeutic target.
  role: amplifier
  biological_scale: ORGANISM
  conforms_to: "sleep_disordered_breathing_intermittent_hypoxia#Ventilatory Control Instability or Chemoreflex Failure"
  biological_processes:
  - preferred_term: nervous system control of respiratory gas exchange
    term:
      id: GO:0002087
      label: regulation of respiratory gaseous exchange by nervous system process
    modifier: ABNORMAL
  evidence:
  - reference: PMID:23721582
    reference_title: Defining phenotypic causes of obstructive sleep apnea. Identification of novel therapeutic targets.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A total of 36% of patients with OSA had minimal genioglossus muscle
      responsiveness during sleep, 37% had a low arousal threshold, and 36% had
      high loop gain.
    explanation: >-
      Quantifies the three non-anatomic traits in a phenotyped cohort, which is
      the evidence that this node is a real and common contributor rather than a
      theoretical refinement.
  - reference: PMID:23721582
    reference_title: Defining phenotypic causes of obstructive sleep apnea. Identification of novel therapeutic targets.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In these patients, loop gain was almost twice as high as patients with a
      Pcrit greater than -2 cm H2O
    explanation: >-
      Shows the trade-off between the anatomic and control arms directly: where
      the airway is comparatively non-collapsible, loop gain is roughly double.
  - reference: PMID:23721582
    reference_title: Defining phenotypic causes of obstructive sleep apnea. Identification of novel therapeutic targets.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This study confirms that OSA is a heterogeneous disorder. Although
      Pcrit-anatomy is an important determinant, abnormalities in nonanatomic
      traits are also present in most patients with OSA.
    explanation: >-
      The study's own conclusion, and the reason this entry curates a
      non-anatomic node alongside the airway-collapse trigger rather than
      treating anatomy as the mechanism.
  downstream:
  - target: Sleep Fragmentation
    description: >-
      A low arousal threshold terminates respiratory events early, before dilator
      recruitment can stabilise the airway, increasing arousal frequency.
    causal_link_type: DIRECT
  - target: Upper Airway Collapse
    description: >-
      High loop gain and poor genioglossus responsiveness convert a marginal
      airway into a repeatedly collapsing one, so these traits act on the
      anatomic trigger rather than bypassing it.
    causal_link_type: DIRECT
- name: Sympathetic Overactivation
  description: >
    Chemoreceptor sensitisation converts a nocturnal, intermittent stimulus into
    a tonic daytime elevation of sympathetic vasoconstrictor outflow that
    persists long after waking - the step that turns a sleep disorder into a
    cardiovascular one - leading to hypertension, arrhythmias, and cardiovascular
    disease.
  role: effector
  biological_scale: ORGANISM
  conforms_to: "sleep_disordered_breathing_intermittent_hypoxia#Sympathetic Overactivation, Oxidative Stress and Vascular Inflammation"
  cell_types:
  - preferred_term: Sympathetic postganglionic neuron
    term:
      id: CL:0011103
      label: sympathetic neuron
  evidence:
  - reference: PMID:38672697
    reference_title: "Unraveling the Complexities of Oxidative Stress and Inflammation Biomarkers in Obstructive Sleep Apnea Syndrome: A Comprehensive Review."
    supports: SUPPORT
    snippet: "The cyclic pattern of intermittent hypoxia in OSAS triggers oxidative
      stress, contributing to cellular damage."
    explanation: "Intermittent hypoxia triggers cellular stress that contributes to
      sympathetic activation and cardiovascular complications."
  - reference: PMID:39595069
    reference_title: "Mitigating Increased Cardiovascular Risk in Patients with Obstructive Sleep Apnea Using GLP-1 Receptor Agonists and SGLT2 Inhibitors: Hype or Hope?"
    supports: SUPPORT
    snippet: "These agents, originally developed for T2D management, have demonstrated
      pleiotropic effects, including significant weight loss, blood pressure reduction,
      and amelioration of endothelial dysfunction and arterial stiffness, along with
      anti-inflammatory benefits, which may be particularly beneficial in OSA."
    explanation: "Indicates that OSA is associated with blood pressure elevation,
      endothelial dysfunction, and arterial stiffness, consistent with sympathetic
      overactivation."
- name: Systemic Inflammation
  description: >
    Intermittent hypoxia activates inflammatory pathways (NF-kB),
    elevating CRP, IL-6, and TNF-alpha. Contributes to metabolic
    dysfunction and atherosclerosis. Curated in parallel with sympathetic
    overactivation rather than downstream of it: the two limbs are additive
    contributors to the vascular consequences, and both are needed to account for
    the hypertension.
  role: effector
  biological_scale: TISSUE
  conforms_to: "sleep_disordered_breathing_intermittent_hypoxia#Sympathetic Overactivation, Oxidative Stress and Vascular Inflammation"
  cell_types:
  - preferred_term: Vascular endothelial cell
    term:
      id: CL:0002139
      label: endothelial cell of vascular tree
  - preferred_term: Macrophage
    term:
      id: CL:0000235
      label: macrophage
  biological_processes:
  - preferred_term: Inflammatory Response
    term:
      id: GO:0006954
      label: inflammatory response
  evidence:
  - reference: PMID:38672697
    reference_title: "Unraveling the Complexities of Oxidative Stress and Inflammation Biomarkers in Obstructive Sleep Apnea Syndrome: A Comprehensive Review."
    supports: SUPPORT
    snippet: "The review delineates the imbalance between pro-inflammatory and anti-inflammatory
      factors in OSAS, leading to heightened oxidative stress."
    explanation: "Confirms that OSA is characterized by an imbalance favoring pro-inflammatory
      factors, resulting in heightened inflammation."
  - reference: PMID:36982552
    reference_title: "Molecular Pathology, Oxidative Stress, and Biomarkers in Obstructive Sleep Apnea."
    supports: SUPPORT
    snippet: "OS and metabolic alterations lead OSAS patients to undergo endothelial
      dysfunction, osteoporosis, systemic inflammation, increased cardiovascular risk,
      pulmonary remodeling, and neurological alterations."
    explanation: "Demonstrates that systemic inflammation is a key pathophysiological
      feature of OSA contributing to multiple complications."
  - reference: PMID:39694586
    reference_title: "Cerebral oxidative stress, inflammation and apoptosis induced by intermittent hypoxia: a systematic review and meta-analysis of rodent data."
    supports: SUPPORT
    snippet: "IH-induced oxidative stress (increased malondialdehyde (MDA) and NADPH
      oxidase (NOX) and decreased superoxide dismutase), increased inflammation (tumour
      necrosis factor-α, NF-κB and inducible nitric oxide synthase), HIF-1 and apoptosis
      evaluated by terminal deoxynucleotidyl transferase dUTP nick-end labelling and
      cleaved caspase-3."
    explanation: "Meta-analysis evidence showing that intermittent hypoxia induces
      inflammation through TNF-α and NF-κB activation."
- name: Ocular Surface Inflammation and Dry Eye Disease
  role: consequence
  biological_scale: TISSUE
  description: >
    Intermittent hypoxia and the associated oxidative stress in OSA drive
    ocular surface and systemic inflammation together with lacrimal gland
    dysfunction (reduced aqueous tear production) and meibomian gland
    dysfunction (dysregulated meibum lipid secretion). The resulting tear
    film instability produces both aqueous-deficient and evaporative dry
    eye disease. Mechanical factors such as face-down sleeping positions,
    habitual eye rubbing, and CPAP airflow leakage or retrograde air
    movement further aggravate meibomian gland dysfunction and ocular
    surface drying.
  cell_types:
  - preferred_term: Meibomian (sebaceous) gland cell
    term:
      id: CL:2000021
      label: sebaceous gland cell
    modifier: ABNORMAL
  biological_processes:
  - preferred_term: Ocular Surface Inflammation
    term:
      id: GO:0006954
      label: inflammatory response
    modifier: INCREASED
  - preferred_term: Response to Oxidative Stress
    term:
      id: GO:0006979
      label: response to oxidative stress
    modifier: INCREASED
  - preferred_term: Meibomian Lipid Metabolism
    term:
      id: GO:0006629
      label: lipid metabolic process
    modifier: DYSREGULATED
  evidence:
  - reference: PMID:42412736
    reference_title: "The Link Between Obstructive Sleep Apnea and Dry Eye Disease: Pathophysiology and Current Updates."
    supports: SUPPORT
    snippet: "Tear film stability is disrupted by inflammation and lacrimal and
      meibomian glands dysfunction, which are caused by intermittent hypoxia and
      associated oxidative stress in OSA."
    explanation: "Establishes the mechanistic link: intermittent hypoxia and oxidative
      stress in OSA drive inflammation and lacrimal/meibomian gland dysfunction that
      destabilize the tear film."
  - reference: PMID:42412736
    reference_title: "The Link Between Obstructive Sleep Apnea and Dry Eye Disease: Pathophysiology and Current Updates."
    supports: SUPPORT
    snippet: "These disruptions result in both aqueous-deficient and evaporative forms of DED."
    explanation: "Confirms that OSA-driven tear film disruption produces both aqueous-deficient
      and evaporative forms of dry eye disease."
  - reference: PMID:42412736
    reference_title: "The Link Between Obstructive Sleep Apnea and Dry Eye Disease: Pathophysiology and Current Updates."
    supports: SUPPORT
    snippet: "This review highlights the multifactorial etiology of OSA-related DED,
      highlighting the roles of systemic and ocular inflammation, lipid metabolism
      dysfunction, and mechanical stress."
    explanation: "Supports the multifactorial mechanism, including ocular inflammation,
      meibomian lipid metabolism dysfunction, and mechanical stress."
phenotypes:
- name: Snoring
  category: Respiratory
  frequency: VERY_FREQUENT
  diagnostic: true
  phenotype_term:
    preferred_term: Snoring
    term:
      id: HP:0025267
      label: Snoring
- name: Witnessed Apneas
  category: Respiratory
  frequency: VERY_FREQUENT
  diagnostic: true
  phenotype_term:
    preferred_term: Sleep Apnea
    term:
      id: HP:0010535
      label: Sleep apnea
- name: Excessive Daytime Sleepiness
  category: Neurological
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Excessive Daytime Somnolence
    term:
      id: HP:0001262
      label: Excessive daytime somnolence
  evidence:
  - reference: PMID:39595069
    reference_title: "Mitigating Increased Cardiovascular Risk in Patients with Obstructive Sleep Apnea Using GLP-1 Receptor Agonists and SGLT2 Inhibitors: Hype or Hope?"
    supports: SUPPORT
    snippet: "Emerging clinical evidence suggests that GLP-1RAs and SGLT2 inhibitors
      can reduce OSA severity and improve daytime sleepiness, potentially reversing
      the adverse cardiovascular effects observed in OSA."
    explanation: "Confirms that daytime sleepiness is a characteristic symptom of
      OSA that can be ameliorated with treatment."
- name: Morning Headaches
  category: Neurological
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Headache
    term:
      id: HP:0002315
      label: Headache
- name: Nocturia
  category: Urological
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Nocturia
    term:
      id: HP:0000017
      label: Nocturia
- name: Dry Eye Disease
  category: Ophthalmologic
  notes: Aqueous-deficient and evaporative dry eye from OSA-related tear film instability
  phenotype_term:
    preferred_term: Dry eye disease
    term:
      id: HP:0001097
      label: Keratoconjunctivitis sicca
  evidence:
  - reference: PMID:42412736
    reference_title: "The Link Between Obstructive Sleep Apnea and Dry Eye Disease: Pathophysiology and Current Updates."
    supports: SUPPORT
    snippet: "Obstructive Sleep Apnea (OSA) and Dry Eye Disease (DED) are increasingly
      recognized as interrelated conditions with significant clinical implications."
    explanation: "Confirms dry eye disease as a recognized ocular comorbidity of obstructive
      sleep apnea."
- name: Cognitive Impairment
  category: Neurological
  frequency: FREQUENT
  notes: Memory, attention deficits
  phenotype_term:
    preferred_term: Cognitive Impairment
    term:
      id: HP:0100543
      label: Cognitive impairment
  evidence:
  - reference: PMID:38672697
    reference_title: "Unraveling the Complexities of Oxidative Stress and Inflammation Biomarkers in Obstructive Sleep Apnea Syndrome: A Comprehensive Review."
    supports: SUPPORT
    snippet: "OSAS significantly impacts quality of life and is associated with increased
      morbidity and mortality, particularly in the cardiovascular and cognitive domains."
    explanation: "Confirms that cognitive impairment is a major domain of morbidity
      in OSA."
  - reference: PMID:39694586
    reference_title: "Cerebral oxidative stress, inflammation and apoptosis induced by intermittent hypoxia: a systematic review and meta-analysis of rodent data."
    supports: SUPPORT
    snippet: "Obstructive sleep apnoea (OSA) contributes to cerebrovascular diseases
      and cognitive decline."
    explanation: "Establishes the link between OSA and cognitive decline, supported
      by rodent model evidence of brain injury from intermittent hypoxia."
- name: Hypertension
  category: Cardiovascular
  frequency: FREQUENT
  notes: Often resistant to treatment
  phenotype_term:
    preferred_term: Hypertension
    term:
      id: HP:0000822
      label: Hypertension
  evidence:
  - reference: PMID:39595069
    reference_title: "Mitigating Increased Cardiovascular Risk in Patients with Obstructive Sleep Apnea Using GLP-1 Receptor Agonists and SGLT2 Inhibitors: Hype or Hope?"
    supports: SUPPORT
    snippet: "These agents, originally developed for T2D management, have demonstrated
      pleiotropic effects, including significant weight loss, blood pressure reduction,
      and amelioration of endothelial dysfunction and arterial stiffness, along with
      anti-inflammatory benefits, which may be particularly beneficial in OSA."
    explanation: "Indicates that blood pressure elevation is a characteristic feature
      of OSA requiring therapeutic intervention."
  - reference: PMID:38672697
    reference_title: "Unraveling the Complexities of Oxidative Stress and Inflammation Biomarkers in Obstructive Sleep Apnea Syndrome: A Comprehensive Review."
    supports: SUPPORT
    snippet: "OSAS-related complications include cardiovascular disorders, neurological
      impairments, metabolic dysfunction, and a potential link to cancer."
    explanation: "Confirms that cardiovascular disorders, including hypertension,
      are a major complication of OSA."
biochemical:
- name: Oxygen Saturation
  presence: Decreased
  context: Nocturnal desaturations
- name: CRP
  presence: Elevated
  context: Systemic inflammation
- name: Catecholamines
  presence: Elevated
  context: Sympathetic activation
genetic:
- name: PHOX2B
  gene_term:
    preferred_term: PHOX2B
    term:
      id: hgnc:9143
      label: PHOX2B
  association: Risk Factor
  notes: Ventilatory control
- name: Craniofacial genes
  association: Risk Factor
  notes: Anatomical predisposition
environmental:
- name: Obesity
  notes: Major modifiable risk factor
  evidence:
  - reference: PMID:11122588
    reference_title: "Longitudinal study of moderate weight change and sleep-disordered breathing"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A 10% increase in weight predicted a 6-fold (95% CI, 2.2-17.0) increase in the odds of developing moderate-to-severe SDB"
    explanation: "Wisconsin Sleep Cohort, measured prospectively at 4-year intervals. The reciprocal finding -- 10% weight loss predicting a 26% AHI reduction -- is what makes this exposure modifiable rather than merely associated."
- name: Alcohol Consumption
  exposure_term:
    preferred_term: exposure to alcohol consumption
    term:
      id: ECTO:0001082
      label: exposure to alcohol consumption
  notes: Alcohol use is associated with OSA (OR 1.33); upper airway muscle
    relaxation is the proposed mechanism
  evidence:
  - reference: PMID:29971810
    reference_title: "Association between obstructive sleep apnea and alcohol, caffeine and tobacco: A meta-analysis"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The odds ratio for OSA increased almost 1.33 times"
    explanation: "Meta-analysis of 14 observational studies; 95% CI 1.10-1.62 (omitted from the snippet because the validator strips bracketed text). PARTIAL, and the note was rewritten: this measures the association, not the airway-relaxation mechanism the note previously asserted, and the authors grade the overall evidence low to very low."
- name: Sedatives
  notes: Worsen airway collapse
  evidence:
  - reference: PMID:16424433
    reference_title: "Unrecognized sleep apnea in the surgical patient: implications for the perioperative setting"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "sedative, analgesic, and anesthetic agents, which can worsen OSAS by decreasing pharyngeal tone"
    explanation: "States the mechanism this annotation records -- loss of pharyngeal tone, plus blunted arousal responses to hypoxia and hypercarbia. OTHER because the quoted sentence is a review's mechanistic synthesis."
- name: Supine Sleep Position
  exposure_term:
    preferred_term: supine sleep position
    term:
      id: XCO:0000084
      label: supine position
  notes: Increases apnea events
  evidence:
  - reference: PMID:28012784
    reference_title: "Positional modification techniques for supine obstructive sleep apnea: A systematic review and meta-analysis"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "found benefit for positional modification techniques in those with supine OSA in terms of reduction in apnea-hypopnea index (AHI) and time spent supine"
    explanation: "Meta-analysis of randomized trials. Interventional rather than observational evidence: preventing supine sleep lowers the AHI, so the position is acting on apnea events rather than merely co-occurring with them. CPAP remained more effective."
- name: Nasal Congestion
  notes: Increases upper airway resistance
  evidence:
  - reference: PMID:11427099
    reference_title: "Chronic nasal congestion at night is a risk factor for snoring in a population-based cohort study"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "for habitual snoring with severe (always or almost always) nasal congestion vs none was 3.0"
    explanation: "Wisconsin Sleep Cohort, 4,916 participants, adjusted for sex, age, body habitus and smoking. PARTIAL and worth reading carefully: the outcome is habitual snoring, and the authors state the association was NOT explained by snorers with frank sleep apnea -- so this supports raised upper airway resistance, not an apnea-event increase."
treatments:
- name: CPAP
  description: Continuous positive airway pressure, gold standard treatment.
  therapeutic_modality: DEVICE
  target_mechanisms:
  - target: Sleep Fragmentation
    treatment_effect: INHIBITS
    description: >-
      Positive pressure splints the pharynx open across the respiratory cycle,
      abolishing the obstruction-arousal cycle and, with it, the intermittent
      hypoxia downstream. Because it removes the events without altering obesity
      or craniofacial anatomy, reversal of the downstream chain under CPAP is
      the causal test that the events themselves drive it.
  - target: Upper Airway Collapse
    treatment_effect: INHIBITS
    description: >-
      Pneumatic splinting acts directly on the anatomic trigger; it does not
      correct the non-anatomic endotypic traits, which is one reason residual
      symptoms persist in some adherent patients.

  treatment_term:
    preferred_term: continuous positive airway pressure ventilation
    term:
      id: NCIT:C124040
      label: Continuous Positive Airway Pressure
  evidence:
  - reference: PMID:42276457
    reference_title: "Positive Airway Pressure Therapy in the Prevention of Obstructive Sleep Apnea Associated Cardiovascular Disease: Controversy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Although PAP therapy improves symptoms, apnea-hypopnea index, and intermediate
      cardiometabolic parameters-particularly among adherent patients-randomized controlled
      trials have yielded inconsistent results for reducing cardiovascular events and mortality."
    explanation: "CPAP (positive airway pressure) improves symptoms and the apnea-hypopnea
      index, establishing it as the primary therapy for OSA, though cardiovascular endpoint
      benefit is adherence-dependent."
  - reference: PMID:41820035
    reference_title: "[Guidelines for the diagnosis and treatment of obstructive sleep apnea in adults (2025)]."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "CPAP is recommended as the default modality due to lower cost (1, A)."
    explanation: The 2025 Chinese Thoracic Society guideline recommends CPAP as the default positive airway pressure modality for obstructive sleep apnea.
- name: BiPAP
  description: Bilevel positive airway pressure for some patients.
  treatment_term:
    preferred_term: bi-level positive airway pressure ventilation
    term:
      id: NCIT:C124039
      label: Biphasic Positive Airway Pressure
  evidence:
  - reference: PMID:42276457
    reference_title: "Positive Airway Pressure Therapy in the Prevention of Obstructive Sleep Apnea Associated Cardiovascular Disease: Controversy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This review examines the pathophysiological mechanisms linking OSA to cardiovascular
      disease, and evaluates current evidence regarding the impact of positive airway pressure
      (PAP) therapy on cardiovascular outcomes and mortality."
    explanation: "Bilevel PAP is a positive airway pressure modality; the review evaluates
      PAP therapy as the mainstay intervention for OSA and its cardiovascular impact."
- name: Oral Appliances
  description: Mandibular advancement devices for mild-moderate OSA.
  treatment_term:
    preferred_term: oral appliance therapy
    term:
      id: NCIT:C157943
      label: Oral Appliance Therapy
  evidence:
  - reference: PMID:26094920
    reference_title: "Clinical Practice Guideline for the Treatment of Obstructive Sleep Apnea and Snoring with Oral Appliance Therapy: An Update for 2015."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We recommend that sleep physicians consider prescription of oral appliances,
      rather than no treatment, for adult patients with obstructive sleep apnea who are intolerant
      of CPAP therapy or prefer alternate therapy."
    explanation: "The AASM/AADSM clinical practice guideline recommends oral appliance therapy
      for adults with OSA who are CPAP-intolerant or prefer an alternative."
- name: Weight Loss
  description: Can significantly reduce or resolve OSA.
  treatment_term:
    preferred_term: dietary intervention
    term:
      id: NCIT:C15447
      label: Dietary Intervention
  evidence:
  - reference: PMID:39595069
    reference_title: "Mitigating Increased Cardiovascular Risk in Patients with Obstructive Sleep Apnea Using GLP-1 Receptor Agonists and SGLT2 Inhibitors: Hype or Hope?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Emerging clinical evidence suggests that GLP-1RAs and SGLT2 inhibitors can
      reduce OSA severity and improve daytime sleepiness, potentially reversing the adverse
      cardiovascular effects observed in OSA."
    explanation: "Weight loss (here achieved pharmacologically with GLP-1RAs) reduces OSA
      severity and improves daytime sleepiness, supporting weight reduction as an OSA-modifying
      intervention."
- name: Positional Therapy
  description: Avoiding supine sleep position.
- name: Surgery
  description: UPPP, maxillomandibular advancement for selected patients.
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: NCIT:C15329
      label: Surgical Procedure
- name: Hypoglossal Nerve Stimulation
  description: Implantable device for CPAP-intolerant patients.
  treatment_term:
    preferred_term: hypoglossal nerve stimulation
    term:
      id: NCIT:C21025
      label: Peripheral Nerve Stimulation
  evidence:
  - reference: PMID:24401051
    reference_title: "Upper-airway stimulation for obstructive sleep apnea."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We evaluated the clinical safety and effectiveness of upper-airway stimulation
      at 12 months for the treatment of moderate-to-severe obstructive sleep apnea."
    explanation: "The STAR trial evaluated upper-airway (hypoglossal nerve) stimulation as
      an implantable therapy for moderate-to-severe OSA in patients unable to adhere to CPAP."
  - reference: PMID:24401051
    reference_title: "Upper-airway stimulation for obstructive sleep apnea."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The median AHI score at 12 months decreased 68%, from 29.3 events per hour to
      9.0 events per hour (P<0.001)"
    explanation: "Hypoglossal nerve stimulation produced a significant 68% reduction in the
      apnea-hypopnea index at 12 months, demonstrating objective efficacy."
diagnosis:
- name: Polysomnography
  description: >-
    Attended in-laboratory polysomnography is the reference standard for
    diagnosing obstructive sleep apnea, quantifying the apnea-hypopnea index,
    and is also preferred for precise assessment of treatment efficacy and
    follow-up.
  diagnosis_term:
    preferred_term: polysomnography
    term:
      id: NCIT:C114185
      label: Polysomnography
  results: Apnea-hypopnea index establishing the presence and severity of obstructive sleep apnea.
  evidence:
  - reference: PMID:41820035
    reference_title: "[Guidelines for the diagnosis and treatment of obstructive sleep apnea in adults (2025)]."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "PSG is the gold standard for diagnosing OSA in adults (1, A)."
    explanation: The 2025 Chinese Thoracic Society guideline designates polysomnography the gold standard diagnostic test for obstructive sleep apnea in adults.
  - reference: PMID:41820035
    reference_title: "[Guidelines for the diagnosis and treatment of obstructive sleep apnea in adults (2025)]."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Screening is recommended for individuals at high risk for OSA who exhibit typical symptoms or physical signs, or who have relevant comorbidities."
    explanation: The guideline recommends screening high-risk individuals with typical symptoms, physical signs, or relevant comorbidities, which precedes diagnostic polysomnography.

discussions:
- discussion_id: kgap_osa_pap_cardiovascular_mechanism
  prompt: Does positive airway pressure (PAP) therapy mechanistically interrupt the OSA-driven cardiovascular pathways (intermittent hypoxia → oxidative stress → sympathetic activation → inflammation) to prevent cardiovascular events, or do improved intermediate parameters not reliably translate to hard cardiovascular endpoints?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - treatments#CPAP
  - treatments#BiPAP
  rationale: >-
    Obstructive sleep apnea has well-established pathophysiological mechanisms linking it to cardiovascular disease (intermittent hypoxia, sympathetic activation, oxidative stress, systemic inflammation). However, randomized controlled trials of PAP therapy show inconsistent results for reducing cardiovascular events and mortality, despite improvements in intermediate markers (apnea-hypopnea index, oxygen saturation, daytime sleepiness) and intermediate cardiometabolic parameters. This suggests that either (1) mechanistic pathways are disrupted by PAP in animal models but less effectively in humans, (2) intermediate-parameter improvement alone does not guarantee hard-endpoint benefit, or (3) treatment efficacy is dependent on phenotype-specific or adherence-dependent factors not yet characterized. The gap is not at the OSA pathophysiology level but at the PAP-therapy-response level: which OSA endotypes truly benefit from PAP, through which mechanism, and under which adherence/severity conditions.
  evidence:
  - reference: PMID:42276457
    reference_title: "Positive Airway Pressure Therapy in the Prevention of Obstructive Sleep Apnea Associated Cardiovascular Disease: Controversy."
    supports: SUPPORT
    snippet: "Although PAP therapy improves symptoms, apnea-hypopnea index, and intermediate cardiometabolic parameters-particularly among adherent patients-randomized controlled trials have yielded inconsistent results for reducing cardiovascular events and mortality."
    explanation: >-
      The cited review documents the discrepancy between PAP's effects on intermediate markers and inconsistent RCT evidence for hard cardiovascular outcomes, highlighting the mechanistic uncertainty about whether PAP-induced improvement in intermediate parameters translates to cardiovascular event prevention.
  proposed_experiments:
  - experiment_id: exp_osa_pap_endotype_stratified_rct
    name: Endotype-stratified PAP randomized cardiovascular outcome trial
    description: >-
      Enroll OSA patients prospectively phenotyped for physiological endotypes
      (loop gain, arousal threshold, upper-airway collapsibility, pharyngeal
      muscle responsiveness) and the hypoxic burden, then randomize to PAP
      versus control with hard cardiovascular endpoints (MACE, cardiovascular
      mortality). Test whether high-hypoxic-burden or sympathetically driven
      endotypes derive cardiovascular benefit that is diluted in unselected
      cohorts, clarifying which OSA endotypes truly benefit mechanistically.
    experiment_type:
      preferred_term: endotype-stratified randomized controlled trial
  - experiment_id: exp_osa_pap_adherence_doseresponse_mace
    name: Adherence-threshold dose-response analysis of PAP and cardiovascular events
    description: >-
      Using telemonitored objective PAP usage, model the dose-response
      relationship between nightly adherence hours and incident major adverse
      cardiovascular events, testing for an adherence threshold above which
      cardiovascular risk reduction emerges. This separates true biological
      inefficacy from undertreatment as the explanation for inconsistent RCT
      results, since prior trials averaged ~3-4 hours nightly use.
    experiment_type:
      preferred_term: adherence dose-response cohort analysis
- discussion_id: kgap_osa_multiorgan_fibrosis
  prompt: >-
    What are the causal pathways by which intermittent hypoxia and sleep
    fragmentation in OSA drive fibrotic remodeling in the lungs, liver, kidneys,
    and heart, and which organ-specific TGF-beta, myofibroblast, and
    ECM-deposition mechanisms are cell-type specific versus shared across tissues?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Intermittent Hypoxia
  - pathophysiology#Sleep Fragmentation
  - pathophysiology#Systemic Inflammation
  - fibrotic_response:pathophysiology#Mesenchymal Cell Activation
  rationale: >-
    Obstructive sleep apnea has established pathophysiological mechanisms linking
    intermittent hypoxia and sleep fragmentation to systemic inflammation and
    oxidative stress. However, the causal contribution of OSA to multi-organ
    fibrotic remodeling remains undercharacterized. Clinical and experimental
    evidence suggests OSA may promote fibrosis in the lungs, liver, kidneys, and
    heart, but the mechanistic details—how intermittent hypoxia-reoxygenation
    initiates TGF-beta signaling, myofibroblast activation, and ECM deposition in
    each organ—are incompletely defined. The degree to which fibrotic remodeling
    is reversible with therapy (e.g., CPAP) and the relative contributions of
    intermittent hypoxia versus sleep fragmentation to fibrotic progression
    remain understudied. Furthermore, organ-specific differences in fibrotic
    susceptibility and the role of tissue-resident macrophages, fibroblasts, and
    endothelial cells in OSA-driven remodeling require clarification. The
    TGF-beta → myofibroblast activation → ECM-deposition chain at issue is the
    conserved process modeled by the `fibrotic_response` module, so this gap is
    also anchored there as a candidate `conforms_to` target should the
    organ-specific evidence mature.
  evidence:
  - reference: PMID:42534659
    reference_title: "Obstructive Sleep Apnea: Epidemiology, Pathophysiology, Complications, Diagnosis, Management, and Emerging Fibrosis-Linked Remodeling."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Within this broader framework, fibrosis-linked structural remodeling emerges as an important yet under-supported dimension of OSA pathobiology"
    explanation: >-
      The cited narrative review explicitly identifies fibrosis-linked remodeling
      as an emerging but under-supported dimension of OSA pathobiology.
  - reference: PMID:42534659
    reference_title: "Obstructive Sleep Apnea: Epidemiology, Pathophysiology, Complications, Diagnosis, Management, and Emerging Fibrosis-Linked Remodeling."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Experimental and clinical evidence suggests that OSA may contribute to remodeling of the lungs, liver, kidneys, and heart, although the strength of the evidence and the degree of causal inference vary across organs."
    explanation: >-
      Acknowledges that OSA may contribute to multi-organ fibrotic remodeling, but
      notes substantial variation in evidence strength and causal clarity across
      tissues.
  proposed_experiments:
  - experiment_id: exp_osa_fibrosis_tissue_responders
    name: Prospective clinical study of OSA-related organ fibrosis progression by tissue type
    description: >-
      Enroll OSA patients with serial imaging (high-resolution CT for lung, MRI
      for hepatic/renal fibrosis staging, echocardiography for cardiac
      fibrosis/stiffness) at baseline and 2-5 years, stratified by hypoxic burden
      and OSA severity, to quantify organ-specific fibrosis progression rates and
      identify which patients develop clinically significant remodeling.
    experiment_type:
      preferred_term: prospective longitudinal imaging cohort study
    decision_criterion: >-
      A hypoxic-burden-dependent increase in organ-specific fibrosis staging over
      2-5 years (dose-response with OSA severity) supports intermittent hypoxia as
      a causal driver of remodeling; no progression above age-matched expectation
      argues against a causal OSA contribution at that organ.
    would_support:
    - pathophysiology#Intermittent Hypoxia
    would_refute:
    - fibrotic_response:pathophysiology#Mesenchymal Cell Activation
  - experiment_id: exp_osa_ih_fibroblast_activation
    name: Mechanistic study of intermittent hypoxia-induced fibroblast activation in organ-specific contexts
    description: >-
      Expose primary fibroblasts isolated from lung, liver, kidney, and cardiac
      tissue to intermittent hypoxia-reoxygenation ex vivo, measuring TGF-beta
      autocrine signaling, α-smooth muscle actin (α-SMA) differentiation,
      pro-fibrotic gene expression (COL1A1, FN1, TIMP1/MMP2 ratio), and responses
      to anti-fibrotic therapies (pirfenidone, nintedanib). Test whether
      organ-specific fibroblast phenotypes show differential sensitivity to
      hypoxic cycles.
    experiment_type:
      preferred_term: organ-specific fibroblast hypoxia-reoxygenation model
    decision_criterion: >-
      Intermittent hypoxia-reoxygenation cycles inducing TGF-beta signaling and
      α-SMA+ myofibroblast conversion above normoxic controls establish that the
      hypoxia signal is sufficient to activate the conserved fibrotic program at
      the fibroblast level; absence of activation localizes the defect upstream
      (systemic/paracrine) rather than to a cell-autonomous fibroblast response.
    would_support:
    - fibrotic_response:pathophysiology#Mesenchymal Cell Activation
    - pathophysiology#Intermittent Hypoxia
  - experiment_id: exp_osa_fibrosis_therapy_reversibility
    name: Randomized trial of OSA therapy efficacy on fibrotic progression
    description: >-
      Enroll newly diagnosed moderate-to-severe OSA patients and randomize to PAP
      therapy versus control, with serial tissue biomarkers (circulating
      procollagen III, hyaluronic acid, tissue inhibitors of metalloproteinases)
      and imaging endpoints (fibrosis staging) at 6, 12, and 24 months. Determine
      whether therapy-induced reductions in intermittent hypoxia and sleep
      fragmentation arrest or reverse early fibrotic changes.
    experiment_type:
      preferred_term: randomized controlled trial with biomarker endpoints
    decision_criterion: >-
      Fibrosis-stage regression or biomarker decline in the PAP arm relative to
      control at 24 months supports OSA-driven remodeling being at least partly
      reversible and hypoxia/fragmentation being active causal drivers; no
      between-arm difference argues the remodeling is fixed or driven by
      OSA-independent comorbidity.
    would_support:
    - pathophysiology#Intermittent Hypoxia
    - pathophysiology#Sleep Fragmentation
    would_refute:
    - fibrotic_response:pathophysiology#Mesenchymal Cell Activation
classifications:
  harrisons_chapter:
  - classification_value: RESPIRATORY
datasets:
- accession: geo:GSE282864
  title: Differential expression profiles of plasma exosomal microRNAs in obstructive sleep apnea patients
  description: Obstructive sleep apnea (OSA) is a prevalent respiratory disorder, with an estimated global prevalence of over one billion individuals, exhibiting a wide spectrum of severity. In this study, clinical data and whole blood samples were obtained from non-OSA individuals and OSA patients.we performed high-throughput sequencing to analyze differential expression of miRNAs between non-OSA exosomes (n=4) and OSA-Exos (n=6). This analysis identified 15 miRNAs exhibited significantly different expression levels between the two groups, with 7 upregulated and 8 downregulated in OSA-Exos compared to CON-Exos.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: BULK_RNA_SEQ
  sample_count: 10
  publication: PMID:40505833
  notes: Identified by GEO DataSets index search for Obstructive Sleep Apnea (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-07-31. Title, sample count, and organism are GEO's own values.
- accession: geo:GSE293433
  title: Differential Expression and Correlation Analysis of Global Transcriptome for Obstructive Sleep Apnea Hypopnea Syndrome
  description: In order to investigate the gene expression patterns and molecular regulatory mechanisms of obstructive sleep apnea hypopnea syndrome (OSAHS), the global transcriptome expression profiles of OSAHS patients and healthy people were analyzed using transcriptome sequencing technology. Differential expression of circular RNA, microRNA, long noncoding RNA, and messenger RNA was investigated between the two groups.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: BULK_RNA_SEQ
  sample_count: 10
  publication: PMID:40264951
  notes: Identified by GEO DataSets index search for Obstructive Sleep Apnea (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-07-31. Title, sample count, and organism are GEO's own values.
- accession: geo:GSE237281
  title: Integrative Analysis of Genome-Wide Epigenetic and Transcriptomic Alterations Reveals Molecular Markers for Diagnosing Pediatric Obstructive Sleep Apnea in Black Females [RNA-Seq]
  description: This study explores the epigentic and transcriptomic changes associated with pediatric obstructive sleep apnea in Black female patients. By analyzing saliva samples, the study identifies dysregulated pathways and specific molecular markers, emphasizing the need for accessible diagnostic tools and addressing healthcare disparities in underrepresented population. The non-invasive approach using saliva samples offers potential for future research and improved diagnostics for pediatric OSA.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: BULK_RNA_SEQ
  sample_count: 19
  publication: PMID:39717585
  notes: Identified by GEO DataSets index search for Obstructive Sleep Apnea (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-07-31. Title, sample count, and organism are GEO's own values.
references:
- reference: DOI:10.1183/16000617.0162-2024
  title: 'Cerebral oxidative stress, inflammation and apoptosis induced by intermittent
    hypoxia: a systematic review and meta-analysis of rodent data'
  findings: []
- reference: DOI:10.3390/biomedicines12112503
  title: 'Mitigating Increased Cardiovascular Risk in Patients with Obstructive Sleep
    Apnea Using GLP-1 Receptor Agonists and SGLT2 Inhibitors: Hype or Hope?'
  findings: []
- reference: DOI:10.3390/ijms24065478
  title: Molecular Pathology, Oxidative Stress, and Biomarkers in Obstructive
    Sleep Apnea
  findings: []
- reference: DOI:10.3390/life14040425
  title: 'Unraveling the Complexities of Oxidative Stress and Inflammation Biomarkers
    in Obstructive Sleep Apnea Syndrome: A Comprehensive Review'
  findings: []
- reference: DOI:10.1159/000553443
  title: 'The Link Between Obstructive Sleep Apnea and Dry Eye Disease: Pathophysiology
    and Current Updates'
  findings: []
📚

References & Deep Research

References

5
DOI:10.1183/16000617.0162-2024
Cerebral oxidative stress, inflammation and apoptosis induced by intermittent hypoxia: a systematic review and meta-analysis of rodent data
No top-level findings curated for this source.
DOI:10.3390/biomedicines12112503
Mitigating Increased Cardiovascular Risk in Patients with Obstructive Sleep Apnea Using GLP-1 Receptor Agonists and SGLT2 Inhibitors: Hype or Hope?
No top-level findings curated for this source.
DOI:10.3390/ijms24065478
Molecular Pathology, Oxidative Stress, and Biomarkers in Obstructive Sleep Apnea
No top-level findings curated for this source.
DOI:10.3390/life14040425
Unraveling the Complexities of Oxidative Stress and Inflammation Biomarkers in Obstructive Sleep Apnea Syndrome: A Comprehensive Review
No top-level findings curated for this source.
DOI:10.1159/000553443
The Link Between Obstructive Sleep Apnea and Dry Eye Disease: Pathophysiology and Current Updates
No top-level findings curated for this source.

Deep Research

2
Disorder ▸

Disorder

  • Name: Obstructive Sleep Apnea
  • Category: Complex
  • Existing deep-research providers: falcon
  • Existing evidence reference count in YAML: 20

Key Pathophysiology Nodes

  • Upper Airway Collapse
  • Intermittent Hypoxia
  • Sleep Fragmentation
  • Sympathetic Overactivation
  • Systemic Inflammation
  • Deep research literature mapping

Citation Inventory (for evidence mapping)

  • DOI:10.1183/16000617.0162-2024
  • DOI:10.3390/biomedicines12112503
  • DOI:10.3390/ijms24065478
  • DOI:10.3390/life14040425
Falcon ▸
Pathophysiology description
Edison Scientific Literature 16 citations 2025-12-17T23:37:05.466909

Pathophysiology description OSA is characterized by recurrent upper-airway collapse during sleep, producing cycles of intermittent hypoxia and reoxygenation and sleep fragmentation. These cycles stabilize HIF‑1α, increase reactive oxygen species (ROS) via NADPH oxidases, activate NF‑κB–dependent inflammation, decrease endothelial nitric oxide (NO) bioavailability, and drive sympathetic overactivity, collectively promoting endothelial dysfunction, vascular remodeling, metabolic dysregulation, and neurocognitive injury (https://doi.org/10.3390/life14040425, Mar 22, 2024) (lavalle2024unravelingthecomplexities pages 1-2, lavalle2024unravelingthecomplexities pages 6-8, lavalle2024unravelingthecomplexities pages 2-3). A recent meta-analysis of rodent intermittent hypoxia (IH), an established OSA model, demonstrates robust increases in cerebral oxidative stress (↑MDA, ↑NADPH oxidase), inflammation (↑TNF‑α, ↑NF‑κB, ↑iNOS), HIF‑1, and apoptosis (↑TUNEL, ↑cleaved caspase‑3), linking IH to brain injury (https://doi.org/10.1183/16000617.0162-2024, Oct 2024) (amine2024cerebraloxidativestress pages 1-2). Clinically, OSA is associated with hypertension, arrhythmias, coronary disease, heart failure, and neurocognitive impairment; sympathetic surges and intrathoracic pressure swings further contribute to cardiovascular stress, while CPAP reliably reduces apneas though cardioprotective effects are inconsistent across endpoints (https://doi.org/10.3390/life14040425, 2024; https://doi.org/10.3390/biomedicines12112503, Nov 2024) (lavalle2024unravelingthecomplexities pages 10-12, karakasis2024mitigatingincreasedcardiovascular pages 4-5).

1) Core Pathophysiology - Intermittent hypoxia/reoxygenation and oxidative stress: IH stabilizes HIF‑1α and augments ROS generation (notably via NADPH oxidase), leading to lipid peroxidation, protein/DNA oxidation, mitochondrial dysfunction, and activation of MAPKs and MMPs; ROS also react with NO to form peroxynitrite, intensifying nitrosative stress (https://doi.org/10.3390/life14040425, 2024) (lavalle2024unravelingthecomplexities pages 6-8). - Systemic and endothelial inflammation: IH and ROS activate NF‑κB, upregulating TNF‑α, IL‑6, IL‑8, and adhesion molecules (E‑selectin, VCAM‑1, ICAM‑1), fostering leukocyte recruitment and endothelial activation (https://doi.org/10.3390/life14040425, 2024) (lavalle2024unravelingthecomplexities pages 9-10, lavalle2024unravelingthecomplexities pages 8-9). - Endothelial dysfunction: Reduced NO bioavailability (eNOS inhibition/ADMA, NO scavenging by superoxide) and increased vasoconstrictors impair vasodilation and accelerate atherogenesis (https://doi.org/10.3390/life14040425, 2024) (lavalle2024unravelingthecomplexities pages 8-9, lavalle2024unravelingthecomplexities pages 9-10). - Autonomic/sympathetic activation: Chemoreflex activation by IH elevates sympathetic tone, producing blood pressure surges and sustained nocturnal hypertension; endothelial dysfunction and prothrombotic pathways add cardiovascular risk (https://doi.org/10.3390/biomedicines12112503, 2024) (karakasis2024mitigatingincreasedcardiovascular pages 4-5, lavalle2024unravelingthecomplexities pages 10-12). - Upper airway collapsibility and neuromuscular control: Sleep-related reduction in dilator muscle drive (e.g., genioglossus) and pharyngeal anatomy increase collapsibility; phenotypic treatment approaches emphasize these endotypes (reviewed) (https://doi.org/10.3390/ijms24065478, Mar 13, 2023) (meliante2023molecularpathologyoxidative pages 1-2). - Ventilatory control instability (loop gain): Respiratory control abnormalities interact with collapsibility to perpetuate apnea cycles; IH amplifies chemoreflex sensitivity (reviewed) (https://doi.org/10.3390/ijms24065478, 2023) (meliante2023molecularpathologyoxidative pages 1-2). - Metabolic dysregulation: OSA-related hypoxemia is linked to oxidative stress, systemic inflammation, and altered antioxidant defenses (↓GSH, ↓SOD, ↓vitamin E), mechanistically tied to insulin resistance and dyslipidemia (https://doi.org/10.3390/life14040425, 2024; https://doi.org/10.3390/ijms24065478, 2023) (lavalle2024unravelingthecomplexities pages 5-6, meliante2023molecularpathologyoxidative pages 1-2). - Neurocognitive/cerebrovascular injury: IH induces cerebral oxidative stress, inflammation, HIF‑1 upregulation, and apoptosis, supporting mechanistic links to cognitive impairment (https://doi.org/10.1183/16000617.0162-2024, 2024) (amine2024cerebraloxidativestress pages 1-2).

2) Key Molecular Players - Genes/proteins (HGNC): HIF1A (hypoxia sensor) (meliante2023molecularpathologyoxidative pages 1-2); NFKB1 (inflammatory TF) (lavalle2024unravelingthecomplexities pages 2-3, lavalle2024unravelingthecomplexities pages 8-9); CYBB/NOX2 (NADPH oxidase; superoxide source) (lavalle2024unravelingthecomplexities pages 6-8); NOS3/eNOS (endothelial NO synthase; reduced NO bioavailability) (lavalle2024unravelingthecomplexities pages 9-10, lavalle2024unravelingthecomplexities pages 8-9); EDN1/ET‑1 (vasoconstrictor; vascular stress) (lavalle2024unravelingthecomplexities pages 8-9); IL6 and TNF (proinflammatory cytokines; correlate with severity) (lavalle2024unravelingthecomplexities pages 9-10, lavalle2024unravelingthecomplexities pages 2-3). See artifact table below for concise ontology mappings. - Chemical entities (CHEBI): ROS, superoxide (O2•–), nitric oxide (NO), peroxynitrite (ONOO–), ADMA (endogenous NOS inhibitor) (lavalle2024unravelingthecomplexities pages 6-8, lavalle2024unravelingthecomplexities pages 8-9, lavalle2024unravelingthecomplexities pages 9-10). - Cell types (CL): Vascular endothelial cells, neutrophils, monocytes/macrophages, astrocytes, microglia, neurons, cardiomyocytes (lavalle2024unravelingthecomplexities pages 9-10, amine2024cerebraloxidativestress pages 1-2, lavalle2024unravelingthecomplexities pages 10-12). - Anatomical locations (UBERON): Upper respiratory tract/pharynx, soft palate, tongue/genioglossus (airway patency), vascular endothelium, brain/hippocampus ( not available; supported generally by 2023–2024 reviews above) (meliante2023molecularpathologyoxidative pages 1-2, amine2024cerebraloxidativestress pages 1-2, lavalle2024unravelingthecomplexities pages 9-10).

Category Name Ontology/System Identifier (HGNC/GO/CL/UBERON/CHEBI) Role/Notes (evidence)
Gene/Protein HIF1A HGNC / Transcription factor HGNC:HIF1A Master hypoxia sensor stabilized by intermittent hypoxia → drives angiogenesis, glycolytic reprogramming and ROS-related inflammation (meliante2023molecularpathologyoxidative pages 1-2, lavalle2024unravelingthecomplexities pages 5-6)
Gene/Protein NFKB1 (NF-κB) HGNC / TF signaling HGNC:NFKB1 Central regulator of inflammatory gene expression induced by IH and ROS (lavalle2024unravelingthecomplexities pages 8-9, lavalle2024unravelingthecomplexities pages 2-3)
Gene/Protein NLRP3 HGNC / Inflammasome HGNC:NLRP3 Activates IL-1β maturation and sterile inflammation in response to IH/ROS (lavalle2024unravelingthecomplexities pages 10-12, lavalle2024unravelingthecomplexities pages 9-10)
Gene/Protein CYBB / NOX2 HGNC / Oxidase HGNC:CYBB (NOX2) NADPH oxidase isoform → major enzymatic source of superoxide in OSA (ROS generation) (lavalle2024unravelingthecomplexities pages 6-8, lavalle2024unravelingthecomplexities pages 8-9)
Gene/Protein NOS3 (eNOS) HGNC / Nitric oxide synthase HGNC:NOS3 (eNOS) Endothelial NO production; reduced NO bioavailability (ADMA, ROS) → endothelial dysfunction (lavalle2024unravelingthecomplexities pages 9-10, lavalle2024unravelingthecomplexities pages 8-9)
Gene/Protein EDN1 (Endothelin-1) HGNC / Vasoconstrictor peptide HGNC:EDN1 (ET-1) Vasoconstrictive mediator increased with endothelial stress → contributes to hypertension/vascular remodeling (lavalle2024unravelingthecomplexities pages 8-9, lavalle2024unravelingthecomplexities pages 5-6)
Gene/Protein IL6 HGNC / Cytokine HGNC:IL6 Proinflammatory cytokine upregulated with IH; correlates with AHI and BMI (lavalle2024unravelingthecomplexities pages 9-10, lavalle2024unravelingthecomplexities pages 2-3)
Gene/Protein TNF (TNF-α) HGNC / Cytokine HGNC:TNF Proinflammatory mediator elevated in OSA; associated with disease severity and cardiovascular risk (lavalle2024unravelingthecomplexities pages 9-10, lavalle2024unravelingthecomplexities pages 2-3)
Chemical entity Reactive oxygen species (ROS) CHEBI / Reactive species CHEBI:reactive_oxygen_species Collective oxidants generated by IH–reoxygenation cycles → lipid/protein/DNA damage and signaling (lavalle2024unravelingthecomplexities pages 6-8, lavalle2024unravelingthecomplexities pages 5-6)
Chemical entity Nitric oxide (NO) CHEBI / Gaseous signaling molecule CHEBI:nitric_oxide Endothelial vasodilator; NO availability reduced by ROS and ADMA leading to vasomotor dysfunction (lavalle2024unravelingthecomplexities pages 8-9, lavalle2024unravelingthecomplexities pages 9-10)
Chemical entity Superoxide (O2•–) CHEBI / Radical CHEBI:superoxide Primary ROS produced by NOX enzymes; reacts with NO to form peroxynitrite → nitrosative stress (lavalle2024unravelingthecomplexities pages 6-8, lavalle2024unravelingthecomplexities pages 5-6)
Chemical entity Peroxynitrite (ONOO–) CHEBI / Reactive nitrogen species CHEBI:peroxynitrite Product of NO + superoxide → promotes protein nitration, endothelial injury and apoptosis (lavalle2024unravelingthecomplexities pages 6-8, lavalle2024unravelingthecomplexities pages 8-9)
Chemical entity ADMA (asymmetric dimethylarginine) CHEBI / Endogenous inhibitor CHEBI:ADMA Endogenous NOS inhibitor implicated in OSA → reduces NO synthesis and worsens endothelial dysfunction (lavalle2024unravelingthecomplexities pages 8-9, lavalle2024unravelingthecomplexities pages 9-10)
Cell type Vascular endothelial cell CL / Vascular cell CL:0000359 (vascular endothelial cell) Primary target of ROS/inflammation → endothelial activation, adhesion molecule upregulation and impaired NO signaling (lavalle2024unravelingthecomplexities pages 9-10, lavalle2024unravelingthecomplexities pages 5-6)
Cell type Neutrophil CL / Innate immune CL:0000775 (neutrophil) Recruited by IL-8 and cytokines; contribute ROS and proteases to vascular/tissue injury (lavalle2024unravelingthecomplexities pages 9-10, lavalle2024unravelingthecomplexities pages 10-12)
Cell type Monocyte / Macrophage CL / Innate immune CL:0000235 (monocyte), CL:0000236 (macrophage) Source of proinflammatory cytokines (TNF, IL-6) and foam-cell formation linking OSA to atherogenesis (lavalle2024unravelingthecomplexities pages 5-6, lavalle2024unravelingthecomplexities pages 2-3)
Cell type Astrocyte CL / CNS glia CL:0000127 (astrocyte) Glial contributor to neuroinflammation under IH → alters neuronal support and blood–brain barrier responses (lavalle2024unravelingthecomplexities pages 10-12)
Cell type Microglial cell CL / CNS immune CL:0000129 (microglial cell) CNS-resident immune cell activated by IH/ROS → promotes neuroinflammation and neuronal injury (lavalle2024unravelingthecomplexities pages 10-12)
Cell type Neuron CL / Neural cell CL:0000540 (neuron) Vulnerable to oxidative stress, inflammation and impaired neurotrophic signaling → cognitive deficits in OSA (, )
Cell type Cardiomyocyte CL / Cardiac muscle cell CL:0000180 (cardiomyocyte) Subject to IH-induced oxidative stress and sympathetic load → remodeling, arrhythmogenesis and dysfunction (lavalle2024unravelingthecomplexities pages 2-3, lavalle2024unravelingthecomplexities pages 5-6)
Anatomical site Upper airway / upper respiratory tract UBERON / Organ system UBERON:0000061 (upper respiratory tract) Primary locus of collapse causing IH; anatomical and soft-tissue contributors determine collapsibility (amine2024cerebraloxidativestress pages 1-2)
Anatomical site Pharynx UBERON / Airway region UBERON:0001004 (pharynx) Narrowed pharyngeal lumen and tissue compliance central to obstruction mechanics (lavalle2024unravelingthecomplexities pages 9-10)
Anatomical site Soft palate UBERON / Oropharyngeal tissue UBERON:0001871 (soft palate) Structural/neuromuscular changes here contribute to airway collapse and airflow limitation (lavalle2024unravelingthecomplexities pages 6-8)
Anatomical site Tongue / Genioglossus muscle UBERON / Muscle UBERON:0001487 (tongue); UBERON:0003676 (genioglossus) Genioglossus neuromuscular tone critical for airway patency; reduced sleep-related activation worsens collapsibility (lavalle2024unravelingthecomplexities pages 10-12)
Anatomical site Vascular endothelium UBERON / Tissue layer UBERON:0004535 (endothelium) Site of early dysfunction in OSA-mediated vascular disease (adhesion molecules, reduced NO) (lavalle2024unravelingthecomplexities pages 9-10, lavalle2024unravelingthecomplexities pages 8-9)
Anatomical site Brain / Hippocampus UBERON / CNS region UBERON:0000955 (brain); UBERON:0002421 (hippocampus) IH-driven oxidative/inflammatory injury here underpins cognitive impairment and memory deficits (, )
GO process Response to hypoxia GO / Biological process GO:0001666 (response to hypoxia) Core transcriptional program activated by IH (HIF-1α stabilization) linking oxygen sensing to downstream pathology (meliante2023molecularpathologyoxidative pages 1-2, lavalle2024unravelingthecomplexities pages 6-8)
GO process Oxidative stress / response to ROS GO / Biological process GO:0006979 (response to oxidative stress) Central mediator of molecular damage and signaling (lipid peroxidation, mitochondrial dysfunction) in OSA (lavalle2024unravelingthecomplexities pages 6-8, lavalle2024unravelingthecomplexities pages 5-6)
GO process Inflammatory response GO / Biological process GO:0006954 (inflammatory response) Systemic and vascular inflammation driven by NF-κB, NLRP3 and cytokines (IL-6, TNF) after IH (lavalle2024unravelingthecomplexities pages 8-9, lavalle2024unravelingthecomplexities pages 9-10)
GO process NF-κB signaling GO / Signaling pathway GO:0038061 (NF-kappaB signaling) Transduces ROS/IH signals to proinflammatory gene expression (lavalle2024unravelingthecomplexities pages 2-3, lavalle2024unravelingthecomplexities pages 8-9)
GO process Nitric oxide biosynthetic process GO / Metabolic process GO:0006809 (nitric oxide biosynthetic process) eNOS-dependent NO production impaired by ADMA and ROS, leading to vasomotor dysfunction (lavalle2024unravelingthecomplexities pages 8-9, lavalle2024unravelingthecomplexities pages 9-10)
GO process Endothelial cell apoptosis GO / Cellular process GO:0006915 (apoptotic process) / GO:0072577 (endothelial apoptosis) ROS, peroxynitrite and inflammatory cytokines promote endothelial cell death and vascular remodeling (lavalle2024unravelingthecomplexities pages 6-8, lavalle2024unravelingthecomplexities pages 8-9)

Table: Concise ontology-annotated table linking key genes, chemicals, cell types, anatomical sites and GO processes to their roles in OSA pathophysiology, with supporting evidence citations (lavalle2024unravelingthecomplexities pages 10-12, lavalle2024unravelingthecomplexities pages 1-2).

3) Biological Processes (GO terms) - Response to hypoxia (GO:0001666): IH stabilizes HIF‑1α and reprograms metabolism and angiogenesis; links hypoxia sensing to downstream injury (meliante2023molecularpathologyoxidative pages 1-2, lavalle2024unravelingthecomplexities pages 6-8). - Response to oxidative stress (GO:0006979): ROS accumulation from NOX and mitochondria drives lipid peroxidation, protein/DNA damage, and signaling cascades (lavalle2024unravelingthecomplexities pages 6-8, lavalle2024unravelingthecomplexities pages 5-6). - Inflammatory response and NF‑κB signaling (GO:0006954; GO:0038061): IH/ROS activate NF‑κB, elevating TNF‑α, IL‑6, IL‑8 and adhesion molecules (lavalle2024unravelingthecomplexities pages 8-9, lavalle2024unravelingthecomplexities pages 9-10, lavalle2024unravelingthecomplexities pages 2-3). - Nitric oxide biosynthetic process (GO:0006809): eNOS-derived NO is reduced by ADMA and ROS scavenging, impairing vasodilation (lavalle2024unravelingthecomplexities pages 8-9, lavalle2024unravelingthecomplexities pages 9-10). - Endothelial cell apoptosis (GO:0072577): ROS and peroxynitrite trigger endothelial injury and apoptosis, advancing vascular remodeling (lavalle2024unravelingthecomplexities pages 6-8, lavalle2024unravelingthecomplexities pages 8-9).

4) Cellular Components - Plasma membrane/caveolae and endothelium: NO/eNOS signaling, adhesion molecule expression, oxidant interactions (lavalle2024unravelingthecomplexities pages 9-10, lavalle2024unravelingthecomplexities pages 8-9). - Mitochondria: ROS generation/dysfunction during IH–reoxygenation (lavalle2024unravelingthecomplexities pages 6-8). - Cytosol/nucleus: NF‑κB activation and HIF‑1α transcriptional programs (lavalle2024unravelingthecomplexities pages 2-3, lavalle2024unravelingthecomplexities pages 6-8). - Extracellular space: Cytokines (TNF‑α, IL‑6), NO/NOx, ADMA, adhesion events (lavalle2024unravelingthecomplexities pages 9-10, lavalle2024unravelingthecomplexities pages 8-9).

5) Disease Progression (sequence of events) - Upper-airway collapsibility during sleep → recurrent apneas/hypopneas → IH/reoxygenation and sleep fragmentation → HIF‑1α stabilization and ROS bursts (NOX/mitochondria) → NF‑κB–driven inflammation and reduced NO bioavailability (ADMA, NO scavenging) → endothelial activation (CAMs), dysfunction, vasoconstriction, and sympathetic surges → vascular remodeling, hypertension, atherogenesis, arrhythmogenic substrate; in brain, IH elevates NOX, TNF‑α, NF‑κB and apoptosis markers → cognitive impairment (https://doi.org/10.3390/life14040425, 2024; https://doi.org/10.1183/16000617.0162-2024, 2024) (lavalle2024unravelingthecomplexities pages 6-8, amine2024cerebraloxidativestress pages 1-2, lavalle2024unravelingthecomplexities pages 9-10).

6) Phenotypic Manifestations (selected HP terms) - Excessive daytime sleepiness (HP:0001254), non-restorative sleep; witnessed apneas/snoring; nocturnal hypoxemia. - Hypertension, notably resistant or nocturnal non-dipping patterns; endothelial dysfunction and increased arterial stiffness (https://doi.org/10.3390/biomedicines12112503, 2024; https://doi.org/10.3390/life14040425, 2024) (karakasis2024mitigatingincreasedcardiovascular pages 4-5, lavalle2024unravelingthecomplexities pages 8-9). - Cardiovascular: coronary artery disease, heart failure, atrial fibrillation; cerebrovascular/cognitive impairment linked to IH-induced brain inflammation/oxidative stress (https://doi.org/10.1183/16000617.0162-2024, 2024) (amine2024cerebraloxidativestress pages 1-2, lavalle2024unravelingthecomplexities pages 10-12).

Recent developments (prioritized 2023–2024) and expert perspectives - Oxidative stress and inflammatory biomarker synthesis: A 2024 comprehensive review collates redox and inflammatory biomarkers in OSA and emphasizes endothelial dysfunction as an early, central lesion; it also highlights inconsistent biomarker standardization and the potential but as-yet unproven benefit of antioxidant adjuncts (https://doi.org/10.3390/life14040425, Mar 22, 2024) (lavalle2024unravelingthecomplexities pages 1-2, lavalle2024unravelingthecomplexities pages 8-9). - Brain-focused IH meta-analysis: 2024 ERS review/meta-analysis confirms IH causally increases brain oxidative stress, inflammation, HIF‑1, and apoptosis across rodent paradigms, strengthening mechanistic plausibility of OSA-related neurocognitive injury (https://doi.org/10.1183/16000617.0162-2024, Oct 2024) (amine2024cerebraloxidativestress pages 1-2). - Cardiovascular/autonomic integration: 2024 review details sympathetic activation, chemoreflex sensitization, endothelial injury, and potential contributions of renin–angiotensin–aldosterone activation in mediating BP surges and persistent nocturnal hypertension; it also discusses emerging cardiometabolic pharmacotherapies (GLP‑1RA, SGLT2i) as adjuncts to improve risk profiles in OSA (https://doi.org/10.3390/biomedicines12112503, Nov 2024) (karakasis2024mitigatingincreasedcardiovascular pages 4-5). - Molecular pathology: A 2023 review synthesizes IH-driven HIF‑1α and ROS pathways, linking to systemic inflammation and endothelial dysfunction, and notes CPAP reverses many molecular alterations while pharmacologic candidates (e.g., antioxidants, neuromodulators) remain investigational (https://doi.org/10.3390/ijms24065478, Mar 13, 2023) (meliante2023molecularpathologyoxidative pages 1-2).

Current applications and real-world implementations - CPAP: Effective at eliminating obstructive events and improving sleepiness; its consistent impact on secondary cardiovascular endpoints remains mixed, underscoring the need for phenotype‑ and mechanism‑guided adjuncts (https://doi.org/10.3390/life14040425, 2024) (lavalle2024unravelingthecomplexities pages 10-12). - Precision phenotyping/endotyping: Targeting anatomic (pharyngeal structure, soft palate, tongue) and non‑anatomic traits (dilator muscle responsiveness, loop gain, arousal threshold) guides use of mandibular advancement devices, positional therapy, hypoglossal nerve stimulation, or pharmacologic neuromodulators (reviewed) (https://doi.org/10.3390/ijms24065478, 2023) (meliante2023molecularpathologyoxidative pages 1-2). - Cardiometabolic pharmacotherapies: GLP‑1 receptor agonists and SGLT2 inhibitors may improve weight, BP, endothelial function, and inflammation, potentially reducing OSA severity and cardiovascular risk; definitive outcome trials in OSA populations are needed (https://doi.org/10.3390/biomedicines12112503, 2024) (karakasis2024mitigatingincreasedcardiovascular pages 4-5).

Relevant statistics and quantitative data - Global burden: OSA affects “approximately 1 billion adults globally,” emphasizing high public health impact (https://doi.org/10.3390/life14040425, 2024) (lavalle2024unravelingthecomplexities pages 1-2). - Resistant hypertension: Up to 80% of resistant hypertension cases may have coexisting OSA, underscoring the strong association and the role of sympathetic activation and endothelial injury (https://doi.org/10.3390/life14040425, 2024) (lavalle2024unravelingthecomplexities pages 10-12). - Oxidative/antioxidant imbalance: Reported reductions in antioxidant defenses include decreased total GSH (OSAS mean 0.389–0.449 nmol/μL vs 0.574–0.713 nmol/μL in controls; p<0.0001), altered GSH/GSSG ratio (p=0.03), reduced vitamin E (p<0.006) and SOD (p<0.001), and increased homocysteine (p<0.02), supporting systemic oxidative stress (https://doi.org/10.3390/life14040425, 2024) (lavalle2024unravelingthecomplexities pages 5-6, lavalle2024unravelingthecomplexities pages 8-9).

Direct quotes supporting key statements - “The cyclic pattern of intermittent hypoxia in OSAS triggers oxidative stress” and “triggers arterial chemoreceptors, heightening sympathetic nervous system activity,” linking ROS and autonomic activation (https://doi.org/10.3390/life14040425, 2024) (lavalle2024unravelingthecomplexities pages 1-2). - IH “stabilizes and accumulates [HIF‑1α], triggering the transcription of various genes” and NOX “convert[s] free oxygen (O2) into superoxide,” anchoring hypoxia-oxidative pathways (https://doi.org/10.3390/life14040425, 2024) (lavalle2024unravelingthecomplexities pages 6-8). - IH in rodents “robustly establishes” increased cerebral oxidative stress, inflammation, HIF‑1, and apoptosis, implicating brain vulnerability to OSA (https://doi.org/10.1183/16000617.0162-2024, 2024) (amine2024cerebraloxidativestress pages 1-2).

Structured annotations for knowledge base - Gene/protein annotations (HGNC): HIF1A; NFKB1; CYBB (NOX2); NOS3 (eNOS); EDN1 (ET‑1); IL6; TNF (lavalle2024unravelingthecomplexities pages 6-8, lavalle2024unravelingthecomplexities pages 9-10, lavalle2024unravelingthecomplexities pages 2-3, lavalle2024unravelingthecomplexities pages 8-9, meliante2023molecularpathologyoxidative pages 1-2). - GO biological processes: response to hypoxia (GO:0001666); response to oxidative stress (GO:0006979); inflammatory response (GO:0006954); NF‑κB signaling (GO:0038061); nitric oxide biosynthetic process (GO:0006809); endothelial cell apoptosis (GO:0072577) (lavalle2024unravelingthecomplexities pages 6-8, lavalle2024unravelingthecomplexities pages 2-3, lavalle2024unravelingthecomplexities pages 8-9). - Cellular components: endothelium/plasma membrane (eNOS/adhesion molecule signaling), mitochondria (ROS), cytosol/nucleus (HIF‑1α/NF‑κB), extracellular space (cytokines/NO/ADMA) (lavalle2024unravelingthecomplexities pages 9-10, lavalle2024unravelingthecomplexities pages 6-8, lavalle2024unravelingthecomplexities pages 8-9). - Cell types (CL): endothelial cells, neutrophils, monocytes/macrophages, astrocytes, microglia, neurons, cardiomyocytes (lavalle2024unravelingthecomplexities pages 9-10, amine2024cerebraloxidativestress pages 1-2, lavalle2024unravelingthecomplexities pages 10-12). - Anatomical locations (UBERON): upper respiratory tract/pharynx, soft palate, tongue/genioglossus, vascular endothelium, brain/hippocampus (meliante2023molecularpathologyoxidative pages 1-2, amine2024cerebraloxidativestress pages 1-2, lavalle2024unravelingthecomplexities pages 9-10). - Chemical entities (CHEBI): ROS, superoxide, NO, peroxynitrite, ADMA (lavalle2024unravelingthecomplexities pages 6-8, lavalle2024unravelingthecomplexities pages 8-9).

Evidence items (with PMIDs if available; DOIs/URLs provided above) - Lavalle et al., 2024 (Life; DOI:10.3390/life14040425) – oxidative stress/inflammation, endothelial dysfunction, sympathetic activation, prevalence statistics (lavalle2024unravelingthecomplexities pages 1-2, lavalle2024unravelingthecomplexities pages 8-9, lavalle2024unravelingthecomplexities pages 2-3, lavalle2024unravelingthecomplexities pages 5-6, lavalle2024unravelingthecomplexities pages 6-8, lavalle2024unravelingthecomplexities pages 9-10). - Amine et al., 2024 (Eur Respir Rev; DOI:10.1183/16000617.0162-2024) – IH meta-analysis demonstrating cerebral oxidative stress, inflammation, HIF‑1, apoptosis (amine2024cerebraloxidativestress pages 1-2). - Karakasis et al., 2024 (Biomedicines; DOI:10.3390/biomedicines12112503) – cardiovascular/autonomic mechanisms, endothelial dysfunction, pharmaco-adjuncts (karakasis2024mitigatingincreasedcardiovascular pages 4-5). - Meliante et al., 2023 (Int J Mol Sci; DOI:10.3390/ijms24065478) – molecular pathology overview, roles for IH, ROS, NF‑κB, endothelial dysfunction; therapeutic notes (meliante2023molecularpathologyoxidative pages 1-2).

Expert analysis The mechanistic framework converges on IH→ROS/HIF‑1α→NF‑κB/inflammation→endothelial dysfunction and sympathetic activation. These processes plausibly explain the multi-organ phenotype of OSA and its cardiometabolic and neurocognitive sequelae. Animal-model meta-analysis provides strong causality for brain injury pathways under IH. Clinically, addressing the anatomical endotype (collapsibility) with CPAP/oral devices/nerve stimulation remains foundational, while cardiometabolic risk may require adjunctive strategies (weight loss, GLP‑1RA/SGLT2i). Biomarker standardization and interventional trials targeting redox/inflammatory axes are priority gaps (amine2024cerebraloxidativestress pages 1-2, karakasis2024mitigatingincreasedcardiovascular pages 4-5, lavalle2024unravelingthecomplexities pages 8-9).

References

  1. (lavalle2024unravelingthecomplexities pages 1-2): Salvatore Lavalle, Edoardo Masiello, Giannicola Iannella, Giuseppe Magliulo, Annalisa Pace, Jerome Rene Lechien, Christian Calvo-Henriquez, Salvatore Cocuzza, Federica Maria Parisi, Valentin Favier, Ahmed Yassin Bahgat, Giovanni Cammaroto, Luigi La Via, Caterina Gagliano, Alberto Caranti, Claudio Vicini, and Antonino Maniaci. Unraveling the complexities of oxidative stress and inflammation biomarkers in obstructive sleep apnea syndrome: a comprehensive review. Life, 14:425, Mar 2024. URL: https://doi.org/10.3390/life14040425, doi:10.3390/life14040425. This article has 83 citations and is from a poor quality or predatory journal.

  2. (lavalle2024unravelingthecomplexities pages 6-8): Salvatore Lavalle, Edoardo Masiello, Giannicola Iannella, Giuseppe Magliulo, Annalisa Pace, Jerome Rene Lechien, Christian Calvo-Henriquez, Salvatore Cocuzza, Federica Maria Parisi, Valentin Favier, Ahmed Yassin Bahgat, Giovanni Cammaroto, Luigi La Via, Caterina Gagliano, Alberto Caranti, Claudio Vicini, and Antonino Maniaci. Unraveling the complexities of oxidative stress and inflammation biomarkers in obstructive sleep apnea syndrome: a comprehensive review. Life, 14:425, Mar 2024. URL: https://doi.org/10.3390/life14040425, doi:10.3390/life14040425. This article has 83 citations and is from a poor quality or predatory journal.

  3. (lavalle2024unravelingthecomplexities pages 2-3): Salvatore Lavalle, Edoardo Masiello, Giannicola Iannella, Giuseppe Magliulo, Annalisa Pace, Jerome Rene Lechien, Christian Calvo-Henriquez, Salvatore Cocuzza, Federica Maria Parisi, Valentin Favier, Ahmed Yassin Bahgat, Giovanni Cammaroto, Luigi La Via, Caterina Gagliano, Alberto Caranti, Claudio Vicini, and Antonino Maniaci. Unraveling the complexities of oxidative stress and inflammation biomarkers in obstructive sleep apnea syndrome: a comprehensive review. Life, 14:425, Mar 2024. URL: https://doi.org/10.3390/life14040425, doi:10.3390/life14040425. This article has 83 citations and is from a poor quality or predatory journal.

  4. (amine2024cerebraloxidativestress pages 1-2): Bayan El Amine, Joey Fournier, Mélanie Minoves, Sébastien Baillieul, Frédéric Roche, Nathalie Perek, Jean-Louis Pépin, Renaud Tamisier, Charles Khouri, Claire Rome, and Anne Briançon-Marjollet. Cerebral oxidative stress, inflammation and apoptosis induced by intermittent hypoxia: a systematic review and meta-analysis of rodent data. European Respiratory Review, 33:240162, Oct 2024. URL: https://doi.org/10.1183/16000617.0162-2024, doi:10.1183/16000617.0162-2024. This article has 7 citations and is from a peer-reviewed journal.

  5. (lavalle2024unravelingthecomplexities pages 10-12): Salvatore Lavalle, Edoardo Masiello, Giannicola Iannella, Giuseppe Magliulo, Annalisa Pace, Jerome Rene Lechien, Christian Calvo-Henriquez, Salvatore Cocuzza, Federica Maria Parisi, Valentin Favier, Ahmed Yassin Bahgat, Giovanni Cammaroto, Luigi La Via, Caterina Gagliano, Alberto Caranti, Claudio Vicini, and Antonino Maniaci. Unraveling the complexities of oxidative stress and inflammation biomarkers in obstructive sleep apnea syndrome: a comprehensive review. Life, 14:425, Mar 2024. URL: https://doi.org/10.3390/life14040425, doi:10.3390/life14040425. This article has 83 citations and is from a poor quality or predatory journal.

  6. (karakasis2024mitigatingincreasedcardiovascular pages 4-5): Paschalis Karakasis, Marios Sagris, Dimitrios Patoulias, Theocharis Koufakis, Panagiotis Theofilis, Aleksandra Klisic, Nikolaos Fragakis, Mohamed El Tanani, and Manfredi Rizzo. Mitigating increased cardiovascular risk in patients with obstructive sleep apnea using glp-1 receptor agonists and sglt2 inhibitors: hype or hope? Biomedicines, 12:2503, Nov 2024. URL: https://doi.org/10.3390/biomedicines12112503, doi:10.3390/biomedicines12112503. This article has 13 citations and is from a poor quality or predatory journal.

  7. (lavalle2024unravelingthecomplexities pages 9-10): Salvatore Lavalle, Edoardo Masiello, Giannicola Iannella, Giuseppe Magliulo, Annalisa Pace, Jerome Rene Lechien, Christian Calvo-Henriquez, Salvatore Cocuzza, Federica Maria Parisi, Valentin Favier, Ahmed Yassin Bahgat, Giovanni Cammaroto, Luigi La Via, Caterina Gagliano, Alberto Caranti, Claudio Vicini, and Antonino Maniaci. Unraveling the complexities of oxidative stress and inflammation biomarkers in obstructive sleep apnea syndrome: a comprehensive review. Life, 14:425, Mar 2024. URL: https://doi.org/10.3390/life14040425, doi:10.3390/life14040425. This article has 83 citations and is from a poor quality or predatory journal.

  8. (lavalle2024unravelingthecomplexities pages 8-9): Salvatore Lavalle, Edoardo Masiello, Giannicola Iannella, Giuseppe Magliulo, Annalisa Pace, Jerome Rene Lechien, Christian Calvo-Henriquez, Salvatore Cocuzza, Federica Maria Parisi, Valentin Favier, Ahmed Yassin Bahgat, Giovanni Cammaroto, Luigi La Via, Caterina Gagliano, Alberto Caranti, Claudio Vicini, and Antonino Maniaci. Unraveling the complexities of oxidative stress and inflammation biomarkers in obstructive sleep apnea syndrome: a comprehensive review. Life, 14:425, Mar 2024. URL: https://doi.org/10.3390/life14040425, doi:10.3390/life14040425. This article has 83 citations and is from a poor quality or predatory journal.

  9. (meliante2023molecularpathologyoxidative pages 1-2): Piero Giuseppe Meliante, Federica Zoccali, Francesca Cascone, Vanessa Di Stefano, Antonio Greco, Marco de Vincentiis, Carla Petrella, Marco Fiore, Antonio Minni, and Christian Barbato. Molecular pathology, oxidative stress, and biomarkers in obstructive sleep apnea. International Journal of Molecular Sciences, 24:5478, Mar 2023. URL: https://doi.org/10.3390/ijms24065478, doi:10.3390/ijms24065478. This article has 104 citations and is from a poor quality or predatory journal.

  10. (lavalle2024unravelingthecomplexities pages 5-6): Salvatore Lavalle, Edoardo Masiello, Giannicola Iannella, Giuseppe Magliulo, Annalisa Pace, Jerome Rene Lechien, Christian Calvo-Henriquez, Salvatore Cocuzza, Federica Maria Parisi, Valentin Favier, Ahmed Yassin Bahgat, Giovanni Cammaroto, Luigi La Via, Caterina Gagliano, Alberto Caranti, Claudio Vicini, and Antonino Maniaci. Unraveling the complexities of oxidative stress and inflammation biomarkers in obstructive sleep apnea syndrome: a comprehensive review. Life, 14:425, Mar 2024. URL: https://doi.org/10.3390/life14040425, doi:10.3390/life14040425. This article has 83 citations and is from a poor quality or predatory journal.